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ABSTRACT 
 
OPTIMIZATION OF A METHOD FOR THE EXTRACTION OF DNA FROM HUMAN 
SKELETAL REMAINS IN FORENSIC CASEWORK 
Sherri Marie Deaton, B.S.  
Western Carolina University (June 2015) 
Director: Dr. Mark R. Wilson 
  
Obtaining full DNA profiles from bone can be challenging due to the inherently low quantity and 
quality of DNA.  An efficient extraction protocol is required to maximize DNA recovery from 
bone samples while minimizing the coextraction of the PCR inhibitors naturally present in bone.     
DNA extraction from bone involves three discrete steps: demineralization, lysis, and purification.  
Demineralization involves incubating bone that has been pulverized into a powder in a chelating 
agent in order to sequester the divalent metal cations that comprise the mineral matrix of bone 
tissue.  This is followed by a lysis step, in which the demineralized bone material is incubated in 
a buffer that disrupts the cellular membrane, releasing the DNA and intracellular components.  
Purification is performed after lysis to separate the DNA from proteins and cellular debris, as 
well as to remove PCR inhibitors.  
Several variables were examined in this study, including the use of three different lysis buffers, 
two different bone types, two different materials for the end caps and impactor bar used in the 
pulverization process, and the interactions between these variables.  The effectiveness of each 
modification in the procedure was assessed using qPCR, which was used to measure mtDNA 
recovery in copies of mtDNA per gram of bone material, as well as by the assessment of 
inhibition using an internal positive control. 
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The actual effectiveness of each lysis buffer varied considerably with bone types examined.  In 
addition, a novel modification to the pulverization step was found to significantly enhance 
mtDNA recovery by reducing inhibition detected in samples.  
The findings of this work suggest that the current methodology is not fully optimized, and 
additional emphasis needs to be placed upon removing inhibitors but also investigating the 
effects of the bone lysate on the pH and ionic strength on the recovery of DNA from bone 
material.  Preliminary work is presented from this study in developing a method for DNA 
extraction from human bone and elucidating the sources of inhibition that are introduced via the 
extraction method itself as well as those naturally present in bone tissue.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Methods of Forensic DNA Analysis 
DNA analysis is a powerful tool for linking suspects to a crime scene and alternatively, 
exonerating the innocent; however, it is not uncommon in forensic casework to be presented with 
very challenging biological samples for analysis.  In cases involving charred remains, missing 
persons, and mass burials, highly degraded bone fragments are often the only obtainable physical 
evidence for human identification.  Numerous challenges exist with extracting DNA from bone; 
the structure and chemical composition of bone make extracting and amplifying DNA difficult, 
and the environmental conditions from which the bone is recovered can dramatically alter the 
preservation state of the bone material and consequently, the integrity and availability of the 
DNA (Ye et al. 2004, Kalmár et al. 2000).  However, because of this unique structure, bone 
tissue is considerably more resistant to degradation than other tissues such as epithelial tissue, 
nervous tissues, etc. (Ye et al. 2004, Loreille et al. 2007). 
Nancy Ritter, editor of the National Institute of Justice Journal, calls the issue of missing 
persons and unidentifiable human remains the “Nation’s Silent Mass Disaster,” noting that as of 
2007, over 40,000 sets of human skeletal remains were unidentifiable using conventional means.  
Until more efficient DNA extraction methods are developed, many of these will remain in 
evidence rooms of medical examiners (2007).  In addition, several government organizations 
such as the Joint POW/MIA Accounting Command-Central Identification Laboratory (JPAC) 
and the Armed Forces DNA Identification Laboratory (AFDIL) work diligently to recover and 
identify the remains of all missing military personnel.  It is estimated that over 83,000 Americans 
are still unaccounted for from the previous conflicts of WWII, the Korean War, Cold War, and 
Vietnam War (Farrell et al. 2013, Edson et al. 2012).   
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As with all challenging bone samples, highly efficient DNA extraction methods are 
required to identify human remains.  In situations involving very degraded bone material, it is 
often very difficult to obtain nuclear DNA for STR analysis (Holland and Parsons 1999).  
Nuclear DNA is typically analyzed in forensic casework by looking at short tandem repeats 
(STRs) present in non-coding regions of nuclear DNA.  STRs are repeating stretches of short 
nucleotide sequences.  The number of these repeated sequences is highly variable, so when 
multiple regions (loci) are examined, the probability of two of these STR profiles being identical 
is extremely unlikely if the individuals are unrelated, often with statistical probabilities of 
discrimination of one in many billions.   
In forensic casework, evidence samples that may be considered robust under normal 
circumstances, such as bloodstains, may become too degraded for nuclear DNA analysis when 
subjected to harsh environmental conditions such as exposure to UV radiation, humidity, etc.  
Hair samples obtained as evidence often lack a root from which nuclear DNA can be extracted, 
and as a result, it is only possible to obtain mtDNA, due to it being significantly more numerous 
in cells  (Melton et al. 2012).  mtDNA can be extracted from casework samples in high quantities 
and because mtDNA is inherited maternally, it is also possible to obtain reference samples in 
missing persons cases from living maternal relatives (Holland and Parsons 1999).              
1.2. Structure and Function of Deoxyribonucleic Acid 
Deoxyribonucleic acid (DNA) is a biopolymer composed of two antiparallel strands of 
deoxyribose molecules connected by phosphate groups, referred to as the sugar phosphate 
backbone.  Connecting each strand to one another are complementary, nitrogenous bases called 
nucleosides, which interact with one another via hydrogen bonding from opposing anti-parallel 
strands.   
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The nitrogenous bases that make up DNA include two purines, adenine (A) and guanine 
(G), which interact via hydrogen bonding with two pyrimidines, thymine (T) and cytosine (C), 
respectively (Fig. 1.1) (Watson and Crick 1953).  In mammalian cells, DNA is found in the 
nucleus of a cell.  It is supercoiled into linear structures called chromosomes (Banfalvi 1986).  In 
addition to nuclear DNA, animal cells contain mitochondrial DNA (mtDNA), present in the 
mitochondria of a cell. 
 
 
 
 
Figure 1.1: Structure and composition of DNA (NLM 2015). 
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Figure 1.2:  Mitochondrial genome showing the control region and hypervariable regions 1 and 2 
(Tilstone 2007). 
 
 
 
Mitochondria are double membrane organelles that are found in most eukaryotic cells 
that play an integral role in cellular respiration, signaling, and differentiation, and are an active 
part of the cell cycle, playing roles in growth, senescence, and apoptosis.  mtDNA is a circular 
chromosome approximately 16,569 base pairs in length that contains 37 genes that code for 
proteins functioning in oxidative phosphorylation.  mtDNA also contains genes which encode 
transfer RNA and ribosomal RNA (Anderson et al. 1981) (Fig. 1.2).  Whereas a eukaryotic cell 
only contains two copies of nuclear DNA, mitochondria are abundant in many cell types, and as 
a result, mtDNA is significantly more numerous in most tissues than nuclear DNA with an 
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average of 500 copies of mtDNA per cell but up to as many as 2000 copies per cell in very 
metabolically active tissues (Satoh and Kuroiwa 1991).  
1.3. Mitochondrial DNA Analysis in Forensic Casework 
As previously mentioned, mtDNA is a circular chromosome found in mitochondria.  A 
non-coding control region exists within the chromosome.  This control region contains the origin 
of replication as well as the origins of transcription from each strand.  Within the control region 
are two hypervariable regions, HVI and HVII (Anderson et al. 1981).  Within these 
hypervariable regions, it is common to find length and sequence polymorphisms, which are 
analyzed to determine the mtDNA type of an individual (Holland and Parsons 1999).  An 
mtDNA type is often expressed as a comparison to the revised Cambridge Reference Sequence 
(rCRS) in order to present a long sequence in shortened form.  The rCRS has been used as a 
mitochondrial DNA reference sequence since 1999 (Andrews et al. 1999).   
In forensic casework, the mtDNA type of the questioned sample found at the crime scene 
(Q) is often compared to known exemplar, or reference samples (K).  In current practice, if both 
the Q and K samples contain identical bases at each position they are said to be in concordance 
with one another and cannot be excluded as originating from the same source.  If a single 
nucleotide polymorphism (SNP) difference is found between any two sequences under 
comparison, then the comparison is deemed inconclusive.  If more than one nucleotide difference 
is present, then the Q sample can be excluded as originating from the same source as the K 
sample (Budowle, Wilson, and DiZinno 1999).  The power of forensic DNA analysis is a result 
of the ability to discriminate one person’s genetic profile from another.  Therefore, in order to 
increase the probability of discrimination of mitochondrial DNA, it is critical to examine a 
greater region of the mitochondrial genome (Coble et al. 2004).  
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1.4. Amplification of DNA Using Polymerase Chain Reaction 
Due to the degradation arising from both the environment and intercellular mechanisms 
of necrosis, DNA extracted from forensically relevant sample types is often low in quantity and 
highly degraded.  While not much can be done to address the degradation of DNA, amplification 
of the available DNA is integral in obtaining sufficient quantities for DNA analysis.  One of the 
biggest advancements in molecular biology occurred in the early 1980’s with the development of 
a method to amplify DNA in vitro.  Polymerase chain reaction (PCR) utilizes an enzyme called 
DNA polymerase to synthesize new strands of DNA from an original template strand (Mullis et 
al. 1986).  The result is amplification of the target strand across orders of magnitude.  Key 
components of PCR include a DNA polymerase to catalyze the addition of nucleotides to the 
growing DNA strand, and DNA primers which are short oligonucleotides, typically about 20 
bases in length, designed to be complementary to the target region of DNA.  A key role of the 
primer is to provide a 3’ hydroxyl group, which is necessary for the incorporation of nucleotides 
by DNA polymerase.  Deoxynucleotide triphosphates (dNTPs) are included in the PCR reaction 
as the substrate of DNA polymerase to be added to the growing DNA strand.  In addition to 
polymerase, primers, and dNTPs, a buffer is included to maintain proper pH and ionic strength, 
and divalent magnesium, which is a critical cofactor for polymerase activity.   
The PCR reaction is driven by thermal cycling, a repeating series of typically three 
temperature changes (Mullis et al. 1986, Saiki et al. 1988).  The first step in PCR is called the 
denaturation step, in which relatively high temperatures weaken and disrupt the hydrogen bonds 
between the base pairs of double-stranded DNA, which results in the formation of single-
stranded DNA.     
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Figure 1.3:  The steps involved in PCR (NCBI 2014). 
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The third step is extension, performed at the temperature for optimum polymerase 
activity and included to extend the newly synthesized strand past the region of the template that 
is complementary to the other primer in the reaction.  This step is carried out for a time interval 
that is determined by the particular PCR product length (Fig. 1.3).  The denaturation, annealing, 
and extension steps are then repeated between 20-40 cycles depending on the quantity of original 
template DNA.  PCR concludes with a final extension step in order to ensure that all single 
stranded DNA strands have been extended.  This is carried out at the temperature required for 
optimal polymerase activity as in the extension step (Mullis et al. 1986).  
1.4.1. Inhibitors of PCR 
 PCR inhibitors are substances that prevent the amplification of DNA in a PCR reaction 
(Wilson 1997).  These substances can inhibit the reaction in a variety of ways, such as by 
binding to or interacting directly with the DNA template; by affecting the availability of 
polymerase cofactors; by binding to and inactivating the DNA polymerase; or by interfering with 
polymerase activity such as during primer extension (Opel et al. 2010, Wilson 1997).  In 
addition, the PCR process is affected by changes in pH, the presence of excessive salts, alcohols, 
and detergents (Wilson 1997, Weyant et al. 1990).  Inhibitors can be removed through additional 
purification steps or dilutions, but these are not without the risk of additional DNA loss and are 
avoided in instances where the amount of extracted DNA is expected to be low (King et al. 
2009).  Certain PCR enhancers, such as bovine serum albumin (BSA) can also reduce the 
inhibitory effects of substances in the PCR reaction, although the precise mechanism is unknown 
(Kreader 1996).  The DNA template to be amplified may itself be compromised from the 
interaction with several inhibitors, such as humic acid, which directly interacts with the DNA 
template (Opel et al. 2010).  
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The mechanisms of many inhibitors found naturally in bone have been studied.  Calcium 
is present in bone material, and is believed to compete directly with divalent magnesium as a 
cofactor for DNA polymerase, therefore reducing the overall PCR efficiency. Another likely 
inhibitor that is found in bone tissue is the protein collagen.  Collagen has been shown to 
decrease the processivity of the DNA polymerase and at high enough concentrations, it has been 
found to interact with the DNA template, particularly in later cycles of the PCR reaction (Opel et 
al. 2010).  Collagen can be removed with the addition of collagenases rather than general 
proteinases, such as proteinase K, which is commonly used in DNA extraction methods (Scholz 
et al. 1998).        
In addition, the PCR reaction can be enhanced with additives such as bovine serum 
albumin (BSA), betaine, dimethyl sulfoxide (DMSO), gelatin, and formamide.  These enhance 
the reaction through different mechanisms.  It is believed that BSA and gelatin stabilize the 
polymerase as well as providing an alternative substrate for many inhibitors (Farell and 
Alexandre 2012, Kreader 1996).  Betaine, DMSO (Frackman et al. 1998 and Henke et al. 1997), 
and formamide reduce secondary structure formation, which occurs frequently in very GC rich 
DNA templates (Bessettii 2007).     
1.4.2. Quantitative Polymerase Chain Reaction (qPCR) 
 Quantitative PCR (qPCR) is widely used to quantify DNA extracted from forensic 
samples, which is critical for downstream procedures such as amplification and sequencing.  
This method uses traditional PCR in order to amplify the DNA; however, the DNA is detected in 
“real time” as it is being amplified, allowing the analyst to determine how much amplifiable 
DNA is present in a casework sample. 
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Figure 1.4:  The mechanism of the 5’ probe in qPCR (Butler 2011). 
 
 
 
As mentioned previously, not all DNA in a sample will be amplifiable due to 
degradation.  Knowing the quantity of amplifiable DNA present in a sample allows the analyst to 
decide whether there is sufficient DNA template to move forward to downstream procedures 
such as further amplification and sequencing (Heid et al. 1996).  Non-specific intercalating 
fluorescent dyes and sequence-specific probes are used in many qPCR assays.  The probes are 
comprised of single stranded oligonucleotides, which are labeled with a fluorescent reporter 
molecule on one end and a quencher molecule that absorbs the fluorescence on the opposite end.  
As DNA polymerase synthesizes the DNA strand, it degrades the probe, separating the reporter 
and the quencher, which prevents the absorbance of the fluorescence by the quencher (Fig. 1.4).  
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This allows a CCD camera to detect emitted fluorescence and therefore provides an accurate and 
effective means of quantifying the number of copies of DNA present in a volume of sample 
(Kavlick et al. 2011).  DNA standards of known concentration are also run in order to quantify 
the DNA present in the unknown by reference to the knowns.     
The cycle threshold (CT) is the number of PCR cycles required for the detected 
fluorescence to exceed a pre-established threshold for detection of the signal above noise.  The 
greater the concentration of DNA present, the fewer amplification cycles are required for the 
fluorescence to exceed the threshold (Fig. 1.5).  Therefore, the CT and the DNA quantity are 
inversely proportionate.  In qPCR, known DNA quantities called standards are analyzed and a 
standard curve is generated as fluorescence as a function of the CT values.  Knowing the 
concentrations of each standard allow a curve to be generated and relative quantification of the 
DNA samples is possible (Heid et al. 1996).  In addition, qPCR assays contain an internal 
positive control (IPC), which is a synthetic DNA template that is amplified with its own primers 
and probe in the PCR reaction. 
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Figure 1.5:  qPCR data showing the threshold line to determine the cycle threshold (CT) value 
(Life Technologies™ 2015). 
 
 
 
The purpose of the IPC is to detect inhibition that may be occurring in the PCR reaction.    
Amplification failure may occur when there is insufficient DNA template in the PCR reaction, or 
when there is adequate amount of DNA available but PCR inhibitors are present.  In the case of 
the former, IPC would still amplify and be detected but the target DNA would not be, and in the 
latter, the IPC would fail to amplify as well as the target DNA.  Varying levels of inhibition can 
be detected by comparing the IPC cycle threshold value (CT) of the non-template control (NTC) 
samples to those observed in the samples.  The non-template controls contain the PCR reaction 
but with molecular biology grade water (MBG) or Tris-EDTA (TE) buffer in place of the DNA 
template.  An elevated IPC CT as compared to this control would indicate that the entire quantity 
of IPC DNA is not being amplified and therefore inhibition is occurring (King et al. 2009). 
In the quantification assay used in this study, samples showing an increase in the IPC CT 
value of each sample compared to the IPC CT of the NTCs and reagent blanks (RB) were 
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considered inhibited.  A slight increase of less than one cycle indicates low levels of inhibition, 
and greater than two cycles indicates moderate levels of inhibition.  If the IPC failed to amplify 
in the PCR reaction, the IPC CT was said to be undetermined.  When this occurred, very high 
levels of inhibition are present.  In addition, a failure to quantify the DNA target from the 
samples in conjunction with an undetermined IPC CT indicates very high levels of inhibitors 
(Kavlick et al. 2011).  In this study, apparent inhibition caused by competition for reagents in the 
DNA standards containing greater than 105 copies/2 μL in the IPC was consistently observed.  
This was detected as a relative increase in the IPC CT of greater than 1 cycle.  This is not true 
inhibition of the PCR reaction, but simply a decrease in PCR efficiency from consumption of the 
reagents.  Examining the IPC CT of bone samples and comparing them to the observed IPC CT 
values of the non-template controls and reagent blanks was a technique utilized in this work to 
assess inhibition.  
1.5. Degradation of DNA Associated with Cell Death 
DNA obtained from human remains is often highly degraded as it is subjected to not only 
environmental degradation processes but also the natural enzymatic and chemical processes that 
occur post mortem.  The process of cell death is initiated approximately 4 minutes post mortem 
as tissues of the body become hypoxic.  In these conditions, oxygen-dependent cellular 
respiration ceases, and in its place anaerobic processes which yield acidic byproducts will begin 
to synthesize ATP (Vass 2001).  The process of DNA degradation begins as pH activated 
lysosomal proteases begin degrading the histone proteins, which contain the nuclear DNA.  
Upon being released from the histone proteins, DNA is then degraded by endogenous nucleases 
into oligonucleotide fragments of random length (Alaeddini et al. 2010).  Endonuclease 
degradation of DNA has distinct characteristics and certain regions are more heavily targeted 
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than others, such as secondary structures.  The degradation of these secondary structures often 
yields high molecular weight (longer) fragments of DNA.  In addition, exogenous nucleases 
from the environment are also a source of DNA degradation.  Other factors can affect the rate 
and size of fragmentation/degradation, such as environmental factors like pH and temperature, as 
well as the concentration of ions present, particularly divalent metals (Lindahl 1993). 
It is important to understand the mechanisms in which DNA is damaged, as these 
modifications will affect the integrity of the extracted DNA.  The two most frequently 
encountered types of damage that occur post mortem in forensically relevant samples are double-
stranded DNA breaks and oxidative damage.  It is impossible to amplify extracted DNA when 
these modifications are present (Gilbert et al. 2003).  Hydrolytic damage to the glycosidic base-
sugar bond results in cleavage of the nitrogenous base, which crosslink formation.  The 
formation of crosslinks prevents successful amplification of the DNA in downstream procedures 
for casework (Alaeddini et al. 2010).  Deamination also occurs in the nitrogenous bases of 
cytosine, adenine, and guanine.  This creates a problem in downstream amplification of the DNA 
template in that mis-incorporation of bases can occur (Pääbo 1989).  
In low copy number samples additional PCR cycles or higher concentrations of reagents 
and polymerase may be added to the reaction.  This will not be effective in cases where the DNA 
is present but highly degraded.  In cases where DNA is highly degraded, MiniSTRs may be 
attempted, which consist of the set of forensic STRs that are present as smaller PCR amplicons 
(Butler 2003).  This has been found to be effective as larger target regions of DNA will 
probabilistically contain more damage sites and smaller target regions are likely to contain less 
(Takahashi et al. 1997).  In cases where the DNA is present in low copy number and is highly 
degraded, mitochondrial DNA analysis is the optimum choice.  Because DNA obtained from 
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human remains is degraded from both environmental and internal processes, it is crucial to 
obtain adequate concentrations of DNA for downstream applications in a gentle method so as to 
not further degrade the extracted DNA.   
1.6. Composition and Structure of Bone and Associated Challenges with DNA Extraction 
Bone tissue is a type of connective tissue consisting of cellular and non-cellular 
components, the latter composed of metals and a collagen matrix (Clarke 2008).  This structure 
renders the bone considerably more resistant to degradation than other bodily tissues and for this 
reason, bone may often be the only enduring physical evidence available for forensic analysis; 
however, the structure of bone presents unique challenges to the typing of DNA for identification 
purposes (Loreille et al. 2007).  Bone tissue consists of two primary structures: cortical bone, a 
solid tissue which lines marrow cavities, and cancellous or trabecular bone, composed of 
trabeculae, which traverse the bone marrow cavities which contain vascular and neural tissue.  In 
cortical bone, the Haversian system or osteon contains the vascular supply as well as neural 
tissue of the bone (Fig. 1.6).  It is comprised of vertical, concentric rings known as lamellae.  
Osteocytes are located in lacunae, which are pockets located within the lamellae.  These 
osteocytes are connected by small channels called canaliculi, which are further connected to the 
central canal, located in the middle of each osteon (Clarke 2008).   
 Bone types are characterized based upon their shapes: short, long, flat, irregular, and 
sesamoid.  Each bone type contains different organization and content of cortical and cancellous 
bone, even within the individual bone.   
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Figure 1.6:  Structure of cortical bone showing cell types, location, and tissue organization (NCI 
[date unknown]). 
 
 
 
Hydroxyapatite, Ca10(PO4)6OH2,   comprises nearly 70% of the mineral content found in bone, 
with small amounts of carbonate, acid phosphate, and magnesium being present as well (Clarke 
2008). 
Type 1 collagen, a structural protein found in connective tissues rich in glycine and 
hydroxyproline, gives bone elasticity and makes up 90% of the organic content in bone (Filippini 
2010).  Collagen is another known inhibitor of PCR, which further illustrates the need of a highly 
efficient purification method in the extraction process (Opel et al. 2010). 
The mineral content of bone along with its solid structure presents a physical barrier to 
efficient DNA extraction, primarily by blocking reagents from accessing the cellular material, 
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which in turn prevents liberation of the DNA.  In addition, the divalent metal cations found in 
bone are inhibitors of PCR; therefore, their removal is critical for downstream forensic analysis 
(Loreille et al. 2007, Kalmár et al. 2000).  The mineral to organic ratio in cortical or cancellous 
bone is consistent across species; however, cortical bone density and ash (hydroxyapatite) 
consistently exceeds that observed in cancellous bone, although the water content and ash: 
organic ratio is higher in cancellous bone (Gong et al. 1964).  This may have implications in the 
amount and type of inhibitors present based on the type of bone analyzed.      
1.7. Inductively Coupled Plasma Optical Emission Spectrometry 
In addition to the metal inhibitors naturally occurring in bone tissue such as iron and 
calcium, it is critical to evaluate any potential introduction of inhibitors from the extraction 
method itself, particularly during the pulverization process.  To further understand the PCR 
inhibition detected in bone samples, ICP-OES was used as a tool to detect and quantify calcium 
and other metals present in the DNA extract from bone.   
ICP-OES is commonly used to detect and quantify trace metals.  The instrument contains 
a torch, comprised of three concentric quartz or silica tubes contained in a copper radio 
frequency (RF) coil (Boss and Fredeen 2004).  RF power is applied to the coil creating an 
oscillating current, resulting in an induced electromagnetic field.  Argon gas flows through the 
torch and is sparked by a tesla coil, ionizing some of the argon gas molecules.  The magnetic 
field accelerates the ionized argon molecules in a process called inductive coupling, resulting in 
collision with other molecules further ionizing the argon into plasma.  The liquid sample is then 
delivered via a peristaltic pump into a nebulizer where it is converted into an aerosol and 
introduced into the plasma in argon gas (Fernández-Martínez et al. 2005, Boss and Fredeen 
2004). 
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Figure 1.7:  Schematic design of an ICP-OES instrument (Ramanaji 2014). 
 
 
 
In the plasma, the sample solvent is removed from the droplets leaving a dry aerosol behind, and 
then the dry aerosol is broken down into gaseous molecules in a process called vaporization 
(Fernández-Martínez et al. 2005, Boss and Fredeen 2004).   
The molecules are broken down further to their component atoms, which are then excited 
and emit radiation. This radiation is separated into its component wavelengths by a 
monochromator, which measures one wavelength at a time, or with a polychromator, which 
measures multiple wavelengths simultaneously.  The separated wavelengths are detected using 
photosensitive detectors such as a charge coupled device (CCD) or photomultiplier tube (PMT).  
ICP-OES can be utilized in not only the detection of metals at low concentrations but also in 
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quantification.  In order to do this, a calibration curve is created with known concentrations of 
analyte and the intensity measured at the appropriate wavelength (Fig. 1.7) (Boss and Fredeen 
2004).   
The ICP-OES is a sensitive instrument that can be utilized to characterize metals found in 
the purified DNA extracts, including calcium, which is a known inhibitor of PCR and present in 
bone tissue in high quantity.  Elucidating which inhibitors are still present in bone extract 
following extraction is a critical step in optimizing extraction methods that are designed to 
remove them.  In this study, DNA extracts were analyzed for the metals chromium, iron, and 
calcium.  Because calcium is a known inhibitor of PCR and so prevalent in osseous tissues, it 
was quantified and compared to inhibition detected via the qPCR results.  
1.8. Current Methodology in DNA Extraction from Osseous Tissues 
 In the extraction of DNA from bone, the surface of bone samples is typically first sanded 
with a Dremel rotary tool (Robert Bosch Tool Corporation, Mt. Prospect, IL) to remove dirt and 
exogenous DNA contamination and then wiped clean with ethanol.  Fragments are cut into small 
sections in order to pulverize the bone fragments more completely.  Prior to pulverization, the 
bone sections are cleaned with bleach (Lorielle et al. 2007) or Terg-A-Zyme® (FBI 2010) 
(Alconox Inc., White Plains, NY), an enzymatic detergent that removes proteinaceous soils, 
body fluids, etc., and finally they undergo a rinse with UV-irradiated molecular biology grade 
water.  The bone material is then allowed to dry prior to pulverization. 
 In order to provide the maximum interaction between the demineralization and lysis 
agents and the bone material, the sample is then pulverized to a fine powder.  This is frequently 
accomplished using either a cryogenic impact grinder such as the 6770 SPEX freezer mill (FBI 
2010) (SPEX® SamplePrep Metuchen, NJ) or a Waring blender (Warring Torrington, CT).  No 
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significant difference in DNA recovery has been observed when these two methods are 
compared (Lorielle et al 2012).  For this study, the 6770 SPEX freezer mill was used set with the 
following parameters: 0 minutes of precool time, 5 minute run time, 2 minute cool time, and a 
rate of 15 cycles per second.  The bone material was placed in a polycarbonate cylinder sample 
vial with a stainless steel impactor bar enclosed by two stainless steel end caps.  The vial was 
then inserted into the freezer mill, which was filled to the appropriate level with approximately 5 
L of liquid nitrogen (SPEX® SamplePrep 2008).     
Following pulverization, the bone material undergoes a process known as 
demineralization in which the bone powder is incubated with a chelating agent such as 
Ethylenediaminetetraacetic acid (EDTA) for different lengths of time ranging from 24 hours 
(FBI 2010) up to three days, sometimes in conjunction with a detergent and other times as a 
separate incubation step at room temperature.  This step is used to sequester divalent metal 
cations present in the mineral matrix of bone tissue (Lorielle et al. 2007).   
Post demineralization, the EDTA can be removed by centrifugation and removal of the 
supernatant, or by concentrating the DNA with a commercially available centrifugal filter unit 
(Lorielle et al. 2007).  In this study, the demineralization and lysis incubation steps were done 
separately and centrifugation was followed by subsequent wash steps to remove the chelated 
metal cations (FBI 2010).   
In preliminary studies, a discoloration was sometimes observed when EDTA was added 
to bone powder, going from a white color to a gray color.  In addition, some gray residue was 
present in the spin column after purification but was not observed in reagent blanks.  Previous 
work that had been done suggested a relationship between discolored samples and higher levels 
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of inhibition.  It is possible that the gray discoloration and debris observed are the result of 
stainless steel contamination as carryover from the pulverization process.  
The stainless steel components used in the SPEX 6770 Freezer Mill are made from 
magnetic 440C steel, which is comprised of iron as well as 0.95-1.2% carbon, 1% manganese, 
1% silicon, 16-18% chromium, 0.75% nickel, 0.5% copper, 0.65% molybdenum, 0.04% 
phosphorus, and 0.3% sulfur.  Iron containing compounds such as heme and chromium are 
known to be inhibitors of PCR (Opel et al. 2010, Thompson et al. 2000).  The SPEX company 
also offers polycarbonate end caps and a polycarbonate-coated impactor bar for use in samples 
where metal contamination needs to be reduced.  The use of polycarbonate end caps and 
impactor bar has not been currently studied for the pulverization of bone material in forensic 
casework.  In this study, the performance of the SPEX polycarbonate end caps and polycarbonate 
coated impactor bar was evaluated.         
1.8.1. Cell Lysis 
An effective lysis buffer maintains pH, provides proper ionic strength, contains a 
detergent to disrupt the phospholipid bilayer of the cellular membrane, and a reducing agent to 
disrupt the disulfide bonds of cysteine amino acid residues found in proteins (Butler 2011).  To 
prevent the degradation of the freed DNA by endonucleases, the broad-spectrum serine protease, 
proteinase K, is added to degrade nucleases.  EDTA, a chelating agent, is also present to 
sequester divalent magnesium cations, a cofactor for nucleases, thus inhibiting their activity.  
Ethylene glycol tetraacetic acid (EGTA) is another chelating agent that is commonly used as it 
has a higher affinity for divalent calcium ions. 
Previously in our lab, a commercially available buffer produced by the Qiagen company, 
lysis buffer ATL, was found to be more effective than SEB (10 mM TRIS, 100 mM NaCl, 39 
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mM dithiolthreitol, 10 mM EDTA, and 2% sodium dodecyl sulfate (SDS) in the digestion of hair 
shafts.  The complete composition of ATL is proprietary; however, based on information 
provided in the MSDS, it can be inferred that buffer ATL does not contain EDTA or EGTA as a 
chelating agent, but does contain SDS at 2.5-10% as a detergent (Qiagen 2013).  The lysis buffer 
BTA produced commercially by Life Technologies™ is specifically formulated for lysis of bone 
material; therefore, it may be effective as a lysis buffer in the development of this method.  The 
chemical composition of BTA is also proprietary, but based on the information provided in the 
MSDS it has been determined that it contains EGTA at 10-30% (w/v) as a chelating agent at an 
unknown concentration and a detergent other than SDS (Life Technologies™ 2011).  To 
maintain consistency between the lysis buffers, dithiothreitol (DTT) was added to each lysis 
buffer for a final concentration of 39 mM, and Proteinase K (Pro-K) was added for a final 
concentration of 1.2 U per lysis reaction, or the amount of enzyme required to turnover one 
micromole of substrate per minute.    
1.8.2. DNA Extraction Methods 
An efficient DNA extraction method is critical to isolate DNA and remove cellular debris 
and excess reagents that may interfere with downstream processes such as amplification.  The 
steps of DNA extraction involve disrupting the cellular membrane to release the contents of the 
cell, separating the nucleic acids from the rest of the cell lysate, and then eluting the DNA into a 
stable solution to prevent degradation.  
Past methods for extracting nucleic acids from tissues and biological samples typically 
involved lysing the cells and then precipitating out the nucleic acids in an alcohol, such as 
ethanol, under high salt conditions.  In a commonly utilized organic extraction method, the 
solvents phenol, isoamyl alcohol, and chloroform are used to extract nucleic acids.    As seen 
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with most methods, cells are lysed with a detergent, and then the lysate is introduced into the 
organic solvents at a certain pH and ionic strength. These conditions are critical to ensure that 
cellular debris remains in the organic phase and nucleic acids are solubilized into the aqueous 
phase.  Alcohol precipitation is then used to extract the nucleic acids from the aqueous fraction. 
Possible limitations of this method include the potential for organic solvent and salt carry-over, 
as well as being labor intensive and time consuming (Hucklenbroich and Scherer 2013). 
Solid phase methods for purification of extracted nucleic acids that use spin columns are 
based on ion exchange and hydrophobic interactions.  Cells are lysed and buffers are then added 
to the lysate which contain a high concentration of chaotropic salts such as guanidinium 
thiocyanate or guanidinium chloride.  Chaotropic agents act by disrupting hydrogen bonding in 
aqueous solution, which enables the negatively charged DNA to bind strongly to the positively 
charged silica substrate via the formation of a salt bridge at a pH of 7 or lower (Hucklenbroich 
and Scherer 2013, Esser et al. 2006).  Cellular debris and inhibitors of PCR are removed by 
several wash and centrifugation steps, and then the DNA is eluted from the substrate with a 
change in the pH and ionic strength (Fig. 1.8) (QIAamp® DNA Mini Kit and QIAamp® DNA 
Blood Mini Kit Handbook 2003). 
In magnetic bead-based purification systems such as Life Technologies™ PrepFiler®, 
DNA can be precipitated out of solution by non-specifically associating with silica-coated 
magnetic beads (Reeve 1997).  In high salt conditions, alcohol can be added to render the DNA 
insoluble, although it does not fully precipitate from solution. Beads can be added to the cell 
lysate prior to or at the same time as a precipitating reagent such as alcohol. 
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Figure 1.8:  A schematic workflow for solid phase DNA extraction methods. (Tilstone 2007). 
 
 
 
As the DNA becomes insoluble, it increases its association with the silica coated 
magnetic beads.  When the sample is placed on a magnetic stand, the silica coated beads and 
associated DNA are drawn to the wall of the reaction tube nearest to the magnet.  Ethanol or 
isopropanol is then used to wash the sample to remove cellular debris, inhibitors, and salts.  This 
particular method is very rapid and does not rely upon centrifugation steps like other methods, 
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which utilize spin columns.  This method also removes the need for multiple tube transfers, 
which are a potential source of DNA loss and contamination (Reeve 1997). 
The use of high concentrations of EDTA in DNA extraction from bone, as well as the 
larger lysate volume, may interfere with optimum binding of DNA to the silica substrates via 
changes in pH.  EDTA and DTT are added to bone material in the demineralization and lysis 
incubations, respectively, and will raise the pH of the cell lysate.  This increase in pH can be 
corrected with the addition of sodium acetate after the lysis incubation, which has been shown to 
enhance DNA recovery (Dukes et al. 2012).     
1.8.3. Quantification of DNA Using qPCR 
A custom assay developed for human mtDNA was used for quantification of extracted 
DNA using an Applied Biosystems 7500 Real-Time PCR System with the 7500 Software 
V2.0.1.  In this assay, a 105 bp region of the mitochondrial genome comprising part of the 
NADH dehydrogenase subunit 5 gene is targeted for amplification, corresponding to base 
positions 13,288 to 13,392 in the rCRS.  This region does not contain many non-human 
homologues, making it ideal for avoiding the amplification of non-human DNA.  
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CHAPTER 2: METHODS AND RESULTS 
 
2.1. Contamination Control for Processing Bone Samples 
All sample processing was performed in laminar flow PCR hoods (AirClean® Systems, 
Creedmoor, NC) that were cleaned with 10% (v/v) sodium hypochlorite, 70% ethanol and UV-
irradiated for 15 minutes.  All microcentrifuge tube racks, microcentrifuge tubes, PCR plates, 
and materials for cutting and sanding bone were UV-irradiated for 15 minutes in a 
Spectrolinker® XL-1000 UV Crosslinker (Spectronics Corporation Westbury, NY) as were all 
reagents that did not contain nucleic acids or enzymes.  The freezer mill pulverization vial and 
associated components (impactor bar and end caps) were cleaned with 10% bleach, 70% ethanol, 
and then UV-irradiated for 15 minutes (FBI 2010).  To prevent contamination, all extractions 
were performed in a separate extraction laboratory and downstream procedures such quantitation 
of amplified DNA were performed in a designated post-amplification laboratory.  Due to the 
inherent sensitivity of mtDNA to contamination, personal protective equipment including a lab 
coat, disposable sleeves, facial mask, and two pairs of nitrile gloves were used and changed 
frequently. 
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2.2. Overview of the Extraction Process 
 
 
 
Figure 2.1:  Extraction method overview for the recovery of mtDNA from human bone. 
 Commercially obtained human bones (Skulls Unlimited International, Inc. Oklahoma 
City, OK) were sanded thoroughly with a Dremel rotary tool (Robert Bosch Tool Corporation, 
Quantification 
Human mtDNA qPCR assay (Kavlick et al. 2011)
Purification
QIAamp® DNA Mini Kit (QIAamp® 2013)
Lysis 
300 μL of lysis buffer SEB, Proteinase K and dithiolthreitol at final 
concentrations of 39 mM and 1.2 U/mL, respectively, are added to 
each sample and incubated overnight (16 hours) at 56°C (FBI 2010)
Demineralization 
0.1 g of bone powder is incubated up to 24 hours in 1.6 mL EDTA 
(0.5 M) on a Nutator and then washed three times with molecular 
biology grade H2O and centrifugation (FBI 2010) 
Sample Prep 
A bone is sanded, wiped with 70% (v/v) EtOH, sonicated in 5% 
(wt/v) Terg-a-Zyme®, and pulverized with SPEX 6770 Freezer Mill 
with stainless steel end caps and impactor bar (FBI 2010) 
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Mt. Prospect, IL) and then wiped down with 70% (v/v) ethanol to remove surface contaminants 
and exogenous DNA.  The sanded bone was then cut into small fragments.  Bone sanding and 
cutting was done in a ductless chemical fume hood (AirClean® Systems, Creedmoor, NC) that 
had been cleaned with 10% (v/v) sodium hypochlorite, 70% (v/v) ethanol, and UV-irradiated for 
15 minutes.  Bone fragments were sonicated for 15 minutes in UV-irradiated 5% (wt/v) Terg-a-
Zyme®, an enzymatic detergent used to remove proteinaceous soils and contaminants, and then 
allowed to air dry (FBI 2010).     
2.2.1. Pulverization of Bone Material 
Pulverization of samples was performed using stainless steel end caps and impactor bar 
in a SPEX 6770 Freezer Mill.  The freezer mill was set with the following parameters: 0 min of 
precool time, 5 min run time, 2 min cool time, and a rate of 15 cycles per second, or back and 
forth cycles of the impactor bar.  A reagent blank was prepared by swabbing the empty 
polycarbonate cylinder, impactor bar and end caps, and then processed in the same manner as the 
bone samples (FBI 2010).  
2.2.2. Demineralization and Lysis 
Each bone sample consisted of approximately 0.1 g of bone powder, which was weighed 
out on an analytical balance (Mettler-Toledo, LLC Columbus, OH) and placed in UV-irradiated 
2 mL microcentrifuge compatible Nalgene tubes.  A volume of 1.6 mL of UV-irradiated 0.5 M 
EDTA was added to each sample, and the samples were incubated for 20-24 hours at room 
temperature on a Nutator.  The reagent blank was also incubated in 1.6 mL EDTA and processed 
alongside all samples from the same extraction experiment.  After the demineralization step, the 
microcentrifuge tubes were centrifuged at 10,900 rpm for 1 minute and the supernatant 
containing EDTA and chelated minerals were removed by micropipette.  The samples were then 
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subjected to three wash steps with UV-irradiated molecular biology grade water (MBG) in an 
attempt to remove sequestered divalent metal cations.  In these washes, 1 mL of UV-irradiated 
MBG H2O was added to each sample, the samples were vortexed to mix and centrifuged for 
another minute, and the supernatant removed by micropipette (FBI 2010).   
For cell lysis, 300 μL of the lysis buffer SEB was then added to each sample and reagent 
blank in conjunction with 1 M dithiothreitol (39 mM final concentration) and 2 μL of 600 U/mL 
Pro-K.  All samples and reagent blanks were then incubated at 56°C on a Nutator overnight (16 
hours) (FBI 2010).   
2.2.3. QIAamp® Spin Column Extraction 
Samples and reagent blanks were purified using the Qiagen QIAamp® DNA Mini kit, 
following the manufacturer’s protocol for DNA purification from blood or body fluids with the 
following modifications: 300 μL of buffer AL, a buffer which provides proper pH and chaotropic 
salts for maximum binding of the DNA to the spin column, was added to each sample and the 
first ten minute incubation was performed at 70°C.  The volume of absolute ethanol used post 
incubation with buffer AL was increased to 400 μL to accommodate the larger sample volume.  
Samples were centrifuged at 10,900 rpm rather than 8,000 rpm.  DNA was eluted from the 
column using a volume of 60 μL of MBG H2O (FBI 2010).   
2.2.4. Quantification of Extracted mtDNA 
The concentration of mtDNA present in copies per 2 μL of sample was assessed using a 
human mtDNA qPCR assay.  Samples were often normalized in studies where samples were not 
diluted to a value of copies of mtDNA per gram of bone material.  Inhibition in samples was 
assessed by a relative comparison of the IPC CT values of the reagent blank (RB) IPC CT  and the 
sample IPC CT values.  In addition, reagent blank (RB) IPC CT values were compared to the IPC 
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CT values of the NTCs, which allowed assessment of inhibition that may be from reagent 
carryover.   
Controls for this assay included three non-template controls containing MBG H2O, Tris-
EDTA buffer, and an Exogenous IPC Blocking Reagent, which blocks the amplification of the 
internal positive control (Applied Biosystems).  The quantification reactions were set up in a 
MicroAmp® 96 well optical plate (Applied Biosystems) with master mix added to each well 
prior to the addition of non-template controls, samples, or standards.  Non-template controls 
were run in duplicate to calculate the average quantity of mtDNA and IPC CT values.  Likewise, 
samples and reagent blanks collected from the extraction phase were run in triplicate in order to 
calculate the average quantity of mtDNA and IPC CT values.  These were capped and the 
standards were added on the unused outermost wells (Kavlick et al. 2011). 
2.3. Examining the Effectiveness of Three Different Lysis Buffers and Interactions with 
Different Bone Types 
To observe the effects of using different lysis buffers in the DNA extraction process, 
samples taken from a human femur and two human ribs were processed following the method 
outlined in section 2.2.  Each sample was treated with 300 μL of one of three lysis buffers, buffer 
ATL, BTA, or SEB, for the overnight lysis incubation.   
2.3.1. Lysis Buffer Performance with Different Bone Types  
Regardless of the lysis buffer utilized, bone samples taken from the femur used in this 
study routinely yielded greater quantities of mtDNA per gram of bone powder than samples from 
human ribs, t(50) = -4.40, p < 001 (Fig. 2.2).  The overall effectiveness of the lysis buffers ATL, 
BTA, and SEB as determined by apparent mtDNA recovery varied with the type of bone 
sampled (Fig. 2.2).  
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Treatment with lysis buffer ATL yielded the highest mean quantity of recovered mtDNA in 
samples taken from femur cross sections, although this was not found to be significantly higher 
than SEB or BTA at the 95% confidence level, F(2,25) = 3.39 p ,= 0.24 (Fig. 2.2).    
  
 
 
 
 
Figure 2.2: The effects of different lysis buffers on mtDNA recovery from two human ribs, 
F(2,22) = 3.47, p = 0.41) and human femur, F(2.25) = 3.39, p = 0.24.  When all variables are 
combined, the femur used in this study routinely yielded greater quantities of mtDNA than the 
ribs, t(50) = -4.40, p < 001.  Error bars represent 95% CI. 
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The IPC CT values of the samples processed from human femur cross sections were elevated by 
1 cycle number relative to the IPC CT of the NTCs; however, they were not elevated 
relative to the RB IPC CT.  This indicates that low levels of inhibition are occurring in both the 
samples and reagent blanks (Kavlick et al. 2011) (Fig. 2.2).  The IPC CT of the reagent blanks 
were elevated relative to those of the NTCs by an average of 0.93 cycles; this was observed in all 
qPCR assays regardless of which lysis buffer was used, F(2,6) = 1.40, p = 0.32 (Fig. 2.3).  
 For human ribs, the difference in the performance of the three lysis buffers was also 
found to be insignificant at the 95% confidence level, F(2,22) = 3.47, p = 0.41 (Fig. 2.2).  
Samples treated with lysis buffer ATL consistently yielded the lowest quantities of mtDNA per 
gram of bone powder obtained from rib material.  The IPC CT was undetermined in 50% of 
samples treated with lysis buffer BTA or SEB, and 100% of samples treated with ATL indicating 
very high levels of inhibition.  Overall, undetermined IPC CT values were observed in 67% of rib 
samples compared to 46% of femur samples. As seen in femur samples, the reagent blank IPC 
CT values in the rib samples were elevated an average of 1.89 cycles higher than those observed 
in the NTC IPC CT (Fig. 2.2).  
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Figure 2.3: A comparison of the reagent blank IPC CT values from human femur samples that 
were treated with either lysis buffer SEB, BTA, or ATL.  No difference in cycle threshold values 
was observed at the 95% confidence level, F(2,6) = 1.40, p = 0.32.  The IPC CT values for the 
reagent blanks showed an increase of approximately 1 cycle relative to the IPC CT of the NTC.  
Error bars represent 95% CI. 
 
 
 
2.4. Comparison of Stainless Steel and Polycarbonate Pulverization Components 
 It was difficult to determine the effectiveness of each lysis buffer as tremendous variation 
in performance was observed within samples processed from a femur and those processed from 
ribs.  Further variation was observed between identical samples processed side by side in 
samples exhibiting high levels of inhibition.  In addition, in some instances a color change was 
observed when EDTA was added to powdered bone samples in the demineralization step.  Upon 
quantification, these samples showed very high levels of inhibition of both the internal positive 
control and the target region of mtDNA.  Dark gray debris was also observed in the spin column 
following purification in these highly inhibited samples (Fig. 2.4).  
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Figure 2.4:  QIAamp® spin columns after extraction.  The sample on the left was pulverized 
with polycarbonate, while the sample on the right used stainless steel.  Debris was present in the 
sample processed with stainless steel. 
 
 
 
Upon examination of the SPEX pulverization end caps and impactor bar, it was observed that 
even after one use, the metal end caps exhibited chipping.  For the data presented in this study, 
only new stainless steel pulverization components were utilized and discarded after a single use.  
Because the composition and structure of bone varies with different types of bone, the 
performance of each lysis buffer was analyzed with respect to these different bone types, in this 
case, a femur and rib.  In addition, the combined effects of bone type, pulverization component, 
and lysis buffer were examined.    Two adjacent cross sections were cut from a human femur.  
These cross sections were again cut in half, and then divided equally to ensure homogeneity of 
sampling, and processed with either polycarbonate or stainless steel end caps and impactor bar. 
The samples were processed following the method outlined in section 2.2, with one third 
of the samples processed with stainless steel treated with lysis buffer ATL, one third treated with 
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BTA, and one third treated with SEB.  The same treatment was performed on samples pulverized 
with polycarbonate pulverization components.  
2.4.1. Optimizing the Bone Pulverization Step   
 The apparent mtDNA recovery with polycarbonate end caps and impactor bar was 
significantly greater at the 95% confidence level than that observed when stainless steel end caps 
and impactor bar were used, t(45) = 2.68, p <001, regardless of the lysis buffer used or bone type 
analyzed (Fig. 2.5).  Moderate levels of inhibition were seen to be occurring in samples 
processed with stainless steel as well as with polycarbonate (Fig. 2.5).  The lysis buffer used did 
not make a difference in the reagent blank IPC CT for samples processed with polycarbonate 
F(2,3) = 2.14, p = 0.27 (Fig. 2.5).   
 For samples processed from a human femur, samples pulverized with polycarbonate end 
caps and impactor bar yielded significantly high recovery of mtDNA, t(26) = 6.48, p < 0.001.  
The performance of the lysis buffers was not affected by the use of stainless steel end caps and 
impactor bar, F(2,14) = 0.20 p = 0.82, or polycarbonate end caps and impactor bar, F(2,9) = 0.15, 
p = 0.86, at the 95% confidence level.   
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Figure 2.5: A compilation of data from different bone types and lysis buffers from samples 
processed with polycarbonate or stainless steel pulverization components.  Regardless of the 
lysis buffer used or bone type, samples pulverized with polycarbonate end caps and impactor bar 
yielded significantly greater mtDNA recovery at the 95% confidence level, t(45) = 2.68, p <001.  
Undetermined IPC CT values were observed in 62% of samples processed with polycarbonate 
and 60% of samples processed with stainless steel, which is indicative of very high levels of 
inhibition.  Error bars represent 95% CI. 
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Figure 2.6: A comparison of quantities of mtDNA recovered from human femur using three 
different lysis buffers and either stainless steel or polycarbonate freezer mill end caps and 
impactor bar.  The samples pulverized with polycarbonate end caps and impactor bar yielded 
significantly high recovery of mtDNA at the 95% confidence level, t(26) = 6.48, p < 0.001.  The 
performance of the lysis buffers was not affected by the use of stainless steel end caps and 
impactor bar, F(2,14) = 0.20 p = 0.82, or polycarbonate end caps and impactor bar, F(2,9) f = 
0.15, p = 0.86, at the 95% confidence level.  Error bars represent 95% CI. 
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Figure 2.7: A comparison of the reagent blank IPC CT values from human femur samples 
processed with either lysis buffer SEB, BTA, or ATL and polycarbonate pulverization 
components.  No difference in cycle threshold values was observed at the 95% confidence level, 
F(2,3) = 2.136, p = 0.265.  The IPC CT values for the reagent blanks are increased by 
approximately 1 cycle relative to the IPC CT of the NTC.  Error bars represent 95% CI. 
 
 
 
Samples processed with polycarbonate, regardless of the lysis buffer used, had reagent 
blank IPC CT values an average of 1.06 cycles higher than those observed with the NTC IPC CT 
(Fig. 2.7).  Likewise, samples processed with stainless steel regardless of lysis buffer used had 
reagent blank IPC CT an average of 0.93 cycles higher than the NTC IPC CT (Fig. 2.3).  This 
difference of approximately one cycle is equivalent to an order of magnitude and represents low 
levels of inhibition. 
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2.4.2. Direct Comparison of Pulverization Components with a Human Rib.   
 To confirm that samples pulverized with stainless steel did exhibit higher levels of 
inhibition and a lower apparent mtDNA yield, an experiment was designed to do a direct 
comparison of rib samples processed with either polycarbonate or stainless steel.  A human rib 
was cut, cleaned, and the fragments equally divided prior to pulverization with either stainless 
steel or polycarbonate end caps and impactor bar.  The samples were lysed with buffer SEB and 
processed according to the method outlined in section 2.2.  In addition, a second quantification 
was performed of the purified mtDNA at a 1:10 dilution in order to observe whether or not any 
difference in mtDNA recovery could be attributed to inhibition.  By diluting out potential 
inhibitors, it was possible to observe if the difference in recovered mtDNA was caused by the 
addition of inhibitors from the use of stainless steel pulverization components.  If there was no 
difference in the quantities of recovered mtDNA at a 1:10 dilution, this suggests that the 
difference is caused by the presence of inhibitors in the undiluted samples.  
 All samples showed inhibition and low recovery of mtDNA; however, the samples 
pulverized using stainless steel components exhibited complete inhibition of samples and IPCs.  
However, when samples from a human rib were pulverized side by side with polycarbonate or 
stainless steel, diluted ten-fold and then quantified, the difference in mean quantity of mtDNA 
recovered using either polycarbonate or stainless steel end caps and impactor bar was found to be 
insignificant at the 95% confidence level, t(4) = 0.53 p = 0.62.  
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Figure 2.8: The mean quantity of mtDNA recovered from human rib when either polycarbonate 
or stainless steel pulverization components were used.  The difference in mtDNA recovery when 
samples were diluted ten-fold was not found to be significant at the 95% confidence level, t(4) = 
0.53 p = 0.62.  Error bars represent 95% CI. 
  
 
 
Even at the 1:10 dilution, a relative increase of the IPC CT was observed in samples 
processed with stainless steel compared to the NTC IPC CT.  This was not observed in samples 
processed with polycarbonate.       
2.5. Bone Sample Mass Effects on mtDNA Recovery from Human Femur 
 Inhibition was observed in mtDNA extracted from bone even when samples were 
pulverized using polycarbonate end caps and impactor bar.  In an attempt to reduce this observed 
inhibition, the mass of bone powder used was reduced to 0.05 g and compared to 0.1 g samples 
quantified from pulverized bone from the same femur cross section.  
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 Samples were processed with either lysis buffer ATL, SEB, or BTA, following the 
method outlined previously in section 2.2.  If divalent calcium was a source of the observed 
inhibition, then increasing the ratio between the chelating agent EDTA and the quantity of bone 
powder used may reduce the levels of inhibition observed.  However, the quantity of recovered 
mtDNA from bone samples of 0.1 g compared to 0.05 g was not found to be significant at the 
95% confidence level, t(16) = 0.35, p =  0.73 (Fig. 2.9).  
 
 
 
 
Figure 2.9:  Mean quantities of recovered mtDNA from small rib using three different lysis 
buffers and either 0.1 g or 0.05 g bone powder.  The difference was not found to be significant at 
the 95% confidence level, t(16) = 0.35, p =  0.73.  No difference in the effectiveness of each lysis 
buffer was observed for samples processed from 0.05 g of bone powder at the 95% confidence 
level, F(2,3) = 0.18, = 0.98) or with samples processed from 0.01 g, F(2,6) = 0.11, p = 0.89).  
Error bars represent 95% CI. 
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2.6. Dilution of Samples to Observe the Behavior of Lysis Buffers with Inhibitors 
To confirm that the difference in apparent mtDNA recovery in samples processed with 
polycarbonate was due to inhibition, samples from two different ribs and a femur were processed 
according to the method outlined in section 2.2 with samples treated with either lysis buffer SEB, 
BTA, or ATL for the lysis incubation.  Following the initial mtDNA quantification of neat 
extracts, dilution series were made of each sample and quantified.  The quantity of recovered 
mtDNA was analyzed, as well as the overall qualitative performance of each lysis buffer in each 
dilution.  
2.6.1. Lysis Buffer Behavior and Dilution Effects with Femur Samples 
 Samples from a femur cross section were processed using polycarbonate pulverization 
components, treated with different lysis buffers and then processed according to the method 
described in section 2.2.  If inhibitors were present in samples, dilution can be used to an extent 
to reduce their effect.  If samples are diluted to a point in which inhibition is no longer detectable 
and there is no difference in mtDNA recovery with different lysis buffers, this strongly suggests 
that the apparent difference in mtDNA recovery in undiluted samples is due to inhibition.  A 
dilution series of the mtDNA extracts from bone were quantified with qPCR.  The quantities of 
mtDNA recovered from the 1:10 was multiplied by ten and five, to estimate the actual quantity 
of the neat and 1:2 diluted samples in the absence of PCR inhibitors. 
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Figure 2.10:  Mean quantities of recovered mtDNA from a femur cross-section using three 
different lysis buffers and polycarbonate SPEX components.  Samples were prepared in a 
dilution series and quantified.  Error bars represent 95% CI. 
 
 
 
 It was observed that the performance of each lysis buffer remained consistent throughout 
the dilution series based on the mtDNA recovery relative to each lysis buffer.  At the 1:10 
dilution, there was no significant difference in lysis buffer performance at the 95% confidence 
level, F(2,3) = 2.87, p = 0.20 (Fig 2.10).  The elevated IPC CT values indicate low levels of 
inhibition in the neat samples and those at a 1:2 dilution (Fig. 2.10).  In the 1:10 dilutions, the 
IPC CT values fell within one cycle of the NTC IPC CT, which indicates that any inhibitors were 
diluted.  Based on the calculated expected values, samples treated with BTA, SEB, or ATL 
exhibited 2%, 4%, and 3% more mtDNA recovery than expected, respectively.   
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 A similar difference was observed with the 1:2 diluted samples.  The actual recovered 
quantities of mtDNA for samples BTA, SEB, and ATL showed 1%, 7%, and 3% more mtDNA 
than expected, respectively.  This indicates that very little inhibition is occurring in these samples 
processed from a femur and any that inhibition that is occurring is not affecting the performance 
of the lysis buffers.  
2.6.2. Lysis Buffer Behavior and Dilution Effects with Large Rib Samples  
 When the same study was performed using a large human rib, samples treated with buffer 
ATL appeared significantly more inhibited than those treated with BTA or SEB in neat samples.  
Complete inhibition of not only the IPC but also the target mtDNA in the sample is observed in 
neat and 1:2 diluted samples.  However, when the samples processed from a large rib were 
diluted ten-fold, no significant difference in recovered mtDNA was observed from either lysis 
buffer ATL, BTA, or SEB, F(2,3) = 0.06, p = 0.94 (Fig. 2.11).  Therefore, the difference of 
mtDNA quantities observed in the neat samples and 1:2 diluted samples is likely due to the 
presence of inhibitors.   
 The IPC CT values for SEB and BTA samples at the 1:10 and 1:2 dilutions were not 
elevated from the NTC IPC CT value indicating that no inhibition is occurring.  In neat samples, 
samples processed with SEB or ATL exhibited 10% and 100% less mtDNA recovery than  
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Figure 2.11:  Mean quantities of recovered mtDNA from large rib using three different lysis 
buffers and polycarbonate SPEX components.  Samples were quantified neat, diluted two fold 
and ten-fold.  Error bars represent ± 95% CI. 
 
 
 
expected, but samples processed with BTA exhibited 25% greater mtDNA recovery than 
expected.  A larger difference between the actual and expected neat mtDNA recovery was 
observed in the 1:2 diluted samples.  Samples processed with BTA or SEB showed 74% and 
67% greater mtDNA recovery than expected, respectively.  However, for samples processed with 
ATL, there was 100% less mtDNA recovered than predicted.  It is possible that large quantities 
of DNA were also diluted out as well as inhibitors.  This illustrates the importance of inhibitor 
removal with samples that contain low copy number DNA.      
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2.6.3. Lysis Buffer Behavior and Dilution Effects of Small Rib Samples  
When the study was repeated with samples processed from a small rib, the same decrease 
in the performance of buffer ATL was observed.   Samples processed with ATL showed 
complete inhibition of the sample and IPC in neat samples (Fig. 2.12).  When samples processed 
from a small rib were diluted ten-fold no significant difference in recovered mtDNA was 
observed between samples treated with different lysis buffers in that the 95% confidence 
intervals overlapped one another.  Therefore, the difference of means observed in the neat 
samples and 1:2 diluted samples is likely due to the presence of inhibitors.   
In neat samples, samples processed with SEB or BTA exhibited 95% and 72 % greater 
mtDNA recovery than expected, but samples processed with ATL exhibited 100% less mtDNA 
recovery than expected.  For the 1:2 diluted samples, samples processed with BTA, SEB or ATL 
showed 26%, 9%, and 67% less mtDNA recovery than expected, respectively.  This suggests that 
a large portion of mtDNA was also diluted with the inhibitors and demonstrates a concern for 
simply diluting samples that are low copy number.   
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Figure 2.12:  Mean quantities of recovered mtDNA from small rib using three different lysis 
buffers and polycarbonate SPEX components.  Samples were quantified neat, diluted two fold 
and ten-fold.  Error bars represent ± 95% CI. 
 
 
 
2.7. Addition of a Chelating Agent to Buffer ATL 
Lysis buffer ATL performed very well in femur samples, but overall poorly in ribs.  A 
possible explanation is that lysis buffer ATL does not contain a chelating agent.  Dilution studies 
of heavily inhibited rib samples showed that when samples were diluted ten-fold, there was not a 
significant difference in the effectiveness of each lysis buffer based on mtDNA recovery.  The 
decrease in the performance of lysis buffer ATL in these samples may be explained by the fact it 
does not contain a chelating agent.  Because lysis buffer ATL performed well with femur 
samples, a chelating agent, EDTA, was added to produce a final concentration of 10 mM to 
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buffer ATL.  A quarter of samples from a large rib were treated with the ATL + 10 mM EDTA, 
one quarter with ATL, one quarter with BTA, and one quarter with SEB.  The samples were 
processed following the protocol outlined previously in section 2.2.  
2.7.1. Enhancing Lysis Buffer ATL with a Chelating Agent 
  In neat samples, ATL containing 10 mM of EDTA was found to significantly reduce 
mtDNA recovery.  However, when diluted 1:10, the difference in mean mtDNA recovery using 
each lysis buffer was not significant at the 95% confidence level, F(3,4 ) = 0.55, p = 0.68 (Fig. 
2.13)  
 
 
 
 
Figure 2.13:  A comparison of mean mtDNA yields from rib samples using the lysis buffers 
SEB, ATL, and BTA, and ATL spiked with 10 mM EDTA.  High levels of PCR inhibition were 
observed.  Error bars represent 95% CI. 
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2.8. Preliminary Work on Comparison of QIAamp® and Prepfiler® 
  Two adjacent cross sections were cut from a human femur and pulverized with stainless 
steel end caps and impactor bar in a SPEX 6770 Freezer Mill.  The samples were processed 
following the protocol outlined in section 2.2 with the following manipulations: all samples were 
treated with lysis buffer SEB, and were purified using either the Qiagen QIAamp® kit or Life 
Technologies™ PrepFiler® magnetic bead-based purification system.  The following 
modifications were made to the manufacturer protocol as these were previously found in our lab 
to be effective for the recovery of mtDNA from hair shafts: for the PrepFiler® purification, 300 
μL of isopropanol was added to each sample.  Qiagen buffer AL was added to samples post lysis 
and samples were incubated at 70°C for ten minutes prior to the addition of absolute ethanol and 
loading onto the spin column to maintain consistency within the protocol (FBI 2010).        
2.8.1. Preliminary Data on Purification Method  
Samples purified using the QIAamp® solid phase extraction kit yielded an overall higher 
mean recovery of mtDNA than those processed with PrepFiler®; however, this was not found to 
be significant at the 95% confidence level, t(4) = 1.82, p = 0.14 (Fig. 2.14).  Interestingly, the 
IPC CT of samples processed with PrepFiler® were an average of 0.80 cycles lower than those in 
samples processed with QIAamp®, suggesting that Prepfiler® may be more efficient in the 
removal of PCR inhibitors. 
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Figure 2.14: mtDNA recovery from human femur cross-sections using either PrepFiler® or 
QIAamp® in conjunction with using stainless steel end caps and impactor bar and lysis buffer 
SEB.  The difference observed in overall mtDNA recovery was insignificant at the 95% 
confidence level, t(4) = 1.82, p = 0.14.  Error bars represent 95% CI. 
 
 
 
2.9. Utilization of Spectroscopy to Identify Metal Carryover in mtDNA Extracts 
In samples processed previously, it was observed that inhibition was still occurring in 
samples that were processed with polycarbonate SPEX components, particularly in rib samples.  
Bone naturally contains many inhibitors of PCR, including large quantities of divalent calcium.  
It had been previously observed that lysis buffer performance appeared to be dependent upon the 
presence of a chelating agent, suggesting that calcium or another metal may be a source of the 
observed inhibition. 
Inductively coupled plasma optical emission spectrometry (ICP-OES) was utilized in 
order to quantify the amount of calcium present in purified mtDNA extracts from bone. The 
Instrument used in this study was the Optima 4100DV (Perkin Elmer, Inc., Waltham, MA).  
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Quantifying the amount of calcium present in samples processed with stainless steel or 
polycarbonate may make it possible to determine if calcium is present in concentrations high 
enough to result in inhibition of the qPCR reaction or to exclude it as a source of the observed 
inhibition.  
 In addition, other metals can be detected, primarily chromium, as it comprises 16-18% of 
440C stainless steel and is a known PCR inhibitor by causing mtDNA damage via crosslinking 
(Thompson et al. 2000).  Previous experiments had determined that samples processed with 
stainless steel components showed significantly higher levels of inhibition than those processed 
with polycarbonate.  In addition to the quantification of calcium in these samples, ICP-OES was 
utilized in order to detect chromium and iron, two other metals suspected to be introduced via the 
pulverization process. 
2.9.1. Inhibition Assay to Determine Calcium Concentrations that Result in qPCR 
Inhibition 
To measure the amount of calcium present in mtDNA extracts using ICP-OES, it was 
necessary to first obtain an estimate of the amount of calcium that may be present in the mtDNA 
extracts.  An inhibition assay was developed to assess calcium inhibition in the qPCR 
quantification assay used in this study, as well as to determine at what concentrations of Ca2+ 
inhibition would be detected.  A stock solution of calcium was prepared in a solution of 
hydrochloric acid (0.084 M Ca2+ pH adjusted to 7.03) from CaHPO4 and serial dilutions were 
created from this stock solution.   
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Figure 2.15:  A calcium inhibition assay in which calcium in the form of CaHPO4 was added to 
a known concentration of mtDNA (HL60) ranging from final concentrations of 3.36 mM to 
0.336 μM. 
 
 
 
Commercially available DNA (HL60 derived from human promyelocytic leukemia cells) 
at a known concentration was treated with varying concentrations of divalent calcium (3.36 mM 
to 0.336 μM).  The calcium preparation and template mtDNA were added separately to the 96 
well plate in 1 μL volumes, respectively.  The samples were then quantified using real time PCR 
following the method described in Kavlick et al. for mtDNA quantification (2011).  Complete 
inhibition of the IPC occurred at a Ca2+ concentration of 3.36 mM (Table 2.1) along with a 99% 
decrease in mtDNA quantity, and a 17% decrease in mtDNA recovery was observed at a Ca2+ 
concentration as low as 3.36 μM (Fig. 2.15).  Inhibition by calcium has been observed as low as 
0.2 μM (Opel et al. 2010).  
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Table 2.1: IPC CT values with known concentrations of added divalent calcium 
 
 
 
2.9.2. Bone Sample Processing 
 A human rib was cut into cross sections and half of the cross sections were pulverized 
with stainless steel and half with polycarbonate SPEX impactor bar and end caps.  The samples 
were then processed following the procedure outlined in section 2.2. 
2.9.3. Preparation of ICP-OES Calcium Standards  
 Calcium standards were prepared using concentrated HNO3 diluted to a final 
concentration of 7% in MBG H2O.  A 150 mL solution of 7% HNO3 was prepared from a 
concentrated HNO3 and used to dilute the standards.  A stock solution of 404.78 ppm was 
prepared by dissolving 0.07 g CaHPO4 in 7 % nitric acid at a final volume of 50 mL.  Seven 
standards were prepared from the stock solution, ranging in concentrations of 404.78 ppm to 
40.480 ppb.    
Ca2+ 
Mean 
IPC CT 
IPC CT 
95% CI 
3.36 mM Undetermined N/A 
336 uM 25.55 0.2 
36.6 uM 25.58 0.6 
3.36 uM 26.22 4 
0.336 uM 25.00 0.5 
0 26.89 4 
Control 
Mean 
IPC CT 
IPC CT 
95% CI 
No HL60, 3.36 mM Ca2+ 32.52 0 
NTC 25.03 0.1 
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2.9.4. Sample Prep ICP-OES 
For the real-time PCR quantification, it was necessary to use 6 μL of the purified mtDNA 
extract, because a total sample volume of at least 1.5 mL is required for ICP-OES analysis.  
Hence, 15 samples were pooled to a total volume of 810 μL.  The pooled samples were adjusted 
to a final volume of 1.5 mL with MBG H2O and 150 μL of 70% HNO3 to a final concentration of 
7%.   
2.9.5. Quantification and Detection of Metals in Bone Extracts Pulverized with 
Polycarbonate or Stainless Steel 
 In an attempt to detect metals in bone extracts and quantify the amounts of calcium 
present, samples from a human rib were pulverized using either polycarbonate or stainless steel 
end caps and impactor bar and then processed according to the protocol outlined in section 2.2. 
2.5.9.1.  Direct quantification of calcium using ICP-OES.  The samples processed with 
stainless steel failed to amplify in the qPCR reaction and all IPC CT values were undetermined 
(Fig. 2.16).  Samples processed with polycarbonate also showed very high levels of inhibition.  
The internal positive control was undetermined for 14/15 samples processed in this study.  A 
tremendous variation in mtDNA recovery was observed between the samples that were 
successfully quantified.  This variation had been observed previously with very inhibited bone 
samples.   
An interesting observation was obtained with one sample during this particular study.  
Sample LR11315.A4 was quantified and exhibited a mtDNA concentration much higher than 
those observed from the other samples that were processed and was the only sample to not show 
an undetermined internal positive control (Fig. 2.17).  The processing of this sample appeared to 
have affected the levels of inhibition in the final extract.  After the lysis incubation, 300 μL of 
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Qiagen buffer AL, which maintains the proper pH and contains chaotropic salts to facilitate the 
binding of mtDNA to the spin column, was added to most samples.  However, an operator error 
with a repeating pipetter resulted in a larger volume (>900 μL) of buffer AL delivered to the 
sample LR11315.A4.  The lysate was equally divided into two aliquots and incubated with the 
other samples.   
 
 
 
 
 
Figure 2.16:  Comparison of mtDNA recovered (copies/g) when either polycarbonate or stainless 
steel SPEX components were used to pulverize samples from the same human rib.    Samples 
pulverized with stainless steel failed to quantify and all IPC CT values were undetermined.  
Sample LR11315.A4 has been excluded.  Error bars represent 95% CI. 
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After the incubation, 400 μL of ethanol was added to each sample, including both 
aliquots of sample LR11315.A4.  The lysate was added to the spin column at a volume of 500 
μL, centrifuged, and the flow through discarded.  This was repeated a total of 4 times for sample 
LR11315.A4 until all the lysate had been added to the spin column and centrifuged out.  Sample 
LR11315.A4 was then processed in the same manner as the other samples during the remaining 
steps of the procedure.  It is possible that the larger volume of buffer AL changed the pH and 
ionic strength and therefore increased binding of mtDNA to the column. The increased volume 
may have also washed away potential inhibitors.  Sample LR11315.A4 was the only sample to 
not have a completely inhibited IPC CT, which suggests that the increased volume allowed for 
more efficient removal of inhibitors.  
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Figure 2.17: mtDNA recovered (copies/g) from a human rib when polycarbonate SPEX 
components were used.  Sample LR11315A.4 showed significantly greater recovery of mtDNA 
than all other samples and an IPC CT that was not undetermined.  Error bars represent 95% CI. 
 
 
 
Table 2.2:  mtDNA recovered (copies/g) when either polycarbonate or stainless steel SPEX 
components were used as well as the quantified calcium concentrations in each sample 
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Calcium was detected and quantified at the wavelength of 315.887 nm on the ICP-OES in 
concentrations of 1.32 and 1.33 ppm (0.033 mM) in samples processed with polycarbonate and 
stainless steel, respectively (Fig. 2.18).  Previous work by Opel et al. demonstrated that divalent 
calcium can cause PCR inhibition at concentrations as low as 0.2 μM (2010).  The calcium 
inhibition assay performed showed a 17% decrease in mtDNA recovery in the presence of 3.36 
μM Ca2+.  Chromium and iron were not detected by the instrument, so if they were present, it 
was at a concentration below the detection limit of the instrument of approximately 0.0002 and 
0.0001 ppm, respectively (Perkin Elmer® 2013).  Because the calcium concentrations are nearly 
the same in samples processed with polycarbonate and samples processed with stainless steel, the 
difference in inhibition levels and mtDNA recovery from the qPCR data cannot be attributed to 
the presence of calcium alone.  This suggests that while calcium is present in the samples and 
causing inhibition, the use of stainless steel pulverization components is contributing to the 
inhibition observed in these bone samples.  
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Figure 2.18:  ICP-OES calcium standard curve at the wavelength of 315.887 nm and corrected 
intensities for samples processed with polycarbonate or stainless steel. 
 
 
 
2.9.6. qPCR of Known mtDNA Concentration Added to Bone Extract 
To better understand the nature of the inhibition observed in bone extracts, known 
concentrations of HL60 DNA were added to the bone extract to examine the effects of the bone 
extract itself on the ability of the mtDNA template to amplify.  In addition, calcium was 
quantified in these mtDNA extracts.  The samples were processed following the method outlined 
in section 2.2 and the ICP-OES standards prepared as in section 2.9.3.  Bone extracts were 
prepared for ICP-OES analysis as described in section 2.9.4. 
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2.9.6.1.  Sample preparation for inhibition study.  All of the extracted mtDNA samples were 
pooled into a 15 mL conical tube, and then several 54 μL aliquots were removed and the 
remaining volume used in the ICP-OES run and prepared as seen in section 2.9.4.  
 To two of the 54 μL aliquots, 6 μL of HL60 mtDNA was added for a final concentration 
of 10 pg/ μL (roughly 15,000 copies/ 2 μL), and to the other two, HL60 mtDNA at a final 
concentration of 1.67 pg/ μL (roughly 2,500 copies/ 2 μL).  The last two of the 54 μL aliquots of 
bone extract had 6 μL of MBG H2O added to serve as negative controls. The six aliquots 
containing mtDNA was then quantified using the qPCR assay outlined in section 2.2.4. 
2.9.6.2.  ICP-OES and qPCR Results from adding known concentrations of mtDNA to bone 
extract.  The qPCR data for the pooled mtDNA extracts indicated moderate levels of inhibition 
(Fig. 2.19) and calcium was quantified at 1.962 ppm (0.04895 mM).  Despite a higher calcium 
concentration than the previously processed rib samples overall (1.334 ppm), lower levels of 
inhibition were observed and higher amounts of mtDNA amplification were obtained (Fig. 2.19).  
 The average quantity of mtDNA recovered from the two aliquots that contained no HL60 
was 2,494.44 ± 186.25 copies/2 μL.  Moderate levels of inhibition were observed with a mean 
IPC CT value of 27.9 ± 0.15 as compared to the NTC IPC CT of 25.39 ± 0.13.  This baseline 
quantity was compared to the observed quantities when HL60 was physically added to bone 
extract.  To assess the levels of inhibition in each sample, the expected quantification values 
were calculated by numerically adding the baseline quantity of mtDNA from the pooled bone 
extract to the positive control mtDNA quantities.   
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Figure 2.19: Comparison of mtDNA recovery and calcium concentration between two rib 
samples processed identically.  Samples processed from the rib LR32315 showed significantly 
greater mtDNA recovery at a confidence level of 95% than samples processed from LR11315, 
t(33) = 10.25, p < 0.001 despite the fact that 1.962 ppm of divalent calcium was measured in 
samples from LR32315 as compared to 1.334 ppm of calcium from samples processed from 
LR11315.  Error bars represent ± 1 standard deviation. 
 
 
 
The difference between the expected and observed HL60 quantities in the 10 pg/μL 
samples was not found to be significant at the 95% confidence level in that the confidence levels 
overlapped (Fig. 2.20).  In the samples containing 1.67 pg/μL of HL60, the difference between 
the expected and observed mtDNA quantities was also found to be insignificant at the 95% 
confidence level in that the confidence levels overlapped (Fig. 2.20). 
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Figure 2.20: Comparison of corrected qPCR data compared to the expected values.  Expected 
values are the positive control quantities plus the quantity observed in the samples of 0 pg/ μL 
HL60.  Error bars represent ± 95% CI. 
 
 
 
2.10. Amplification of HVI and HVII 
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associated reagent blanks were selected to be amplified with human-specific mtDNA primer sets 
and the PCR products quantified on the Agilent Technologies® 2100 Bioanalyzer® using the 
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CTC CAT GC-3’) and D1 (H 409, 5’-CTG TTA AAA GTG CAT ACC GCC-3’).  For PCR, an 
ABI Model 9700 thermal cycler was utilized with the following cycling parameters: 95°C for 9 
min, then 36 cycles of 95°C for 10 s, 60°C for 30 s, 72°C for 30 s, and a final extension of 72°C 
for 10 min (FBI 2010).   
 
 
 
 
 
 
 
Table 2.3:  Master mix calculations for amplification of HVI and HVII from mtDNA extracted 
from human bones (FBI 2010) 
Reagent μL/Reaction Final Concentration 
DNA Template  10 - 
MBG H2O 4 - 
GeneAMP® 10x PCR buffer 2.5 1 x 
Primer Pair 10 uM each 1.5 0.6 uM 
BSA (1.6 μg/μL) 2.5 0.16 μg/μL 
dNTP mix 10 mM 0.5 0.2 mM 
MgCl2 25 mM 1.5 2.5 mM 
Amplitaq Gold® DNA 
polymerase (5 U/μL) 
1 5 U 
Total Volume 25 - 
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2.10.1. Amplification of HVI and HVII of mtDNA Extracted from Human Bone 
A correlation between the quantity of mtDNA from the qPCR and the amount of 
amplified mtDNA as assessed from the Bioanalyzer® run was observed (R2 =0.77716).  In 
general, samples that had a significant amount of inhibition when analyzed with qPCR showed 
lower concentrations of amplified mtDNA quantified with the Bioanalyzer®.  Samples that 
quantified with the mtDNA assay used in this study also showed successful amplification of the 
HVI and HVII regions.  
 
 
 
 
 
 
Figure 2.21:  Correlation between the quantity of mtDNA observed from qPCR and the 
Bioanalyzer®. 
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2.11. Quantification of Nuclear DNA from Purified Bone Extracts 
To see if samples containing large quantities of mtDNA also contained amplifiable 
nuclear DNA, selected samples of purified bone-extracted DNA were quantified for nuclear 
DNA using the Life Technologies™ Quantifiler® HP and Trio Quantification Kit (Thermo 
Fisher Scientific Corporation, Carlsbad, CA).  The Quantifiler® HP assay contains four nuclear 
DNA targets: a short and long autosomal PCR amplicon of 80 and 214 bases in length, 
respectively, a Y chromosome target of 75 bases in length, and 130 base long internal positive 
control.  It is a 5’ endonuclease assay that uses TaqMan® probes.  The ratio of the large 
amplicon over the small amplicon describes what is known as the degradation index, which 
provides information of how degraded the extracted DNA may be.  A third target on the Y 
chromosome can be used to determine the sex of the individual.  The assay was run on an 
Applied Biosystems® 7500 Real-Time PCR instrument and analyzed with HID HIG Real-Time 
PCR Analysis Software v1.2 Real-Time PCR Analysis Software v1.2.   
2.11.1. Nuclear DNA Quantification from Human Rib 
The difference in effectiveness of each lysis buffer was not found to be significant at the 
95% confidence level rib samples pulverized with either polycarbonate or stainless steel end caps 
and impactor bar (Table 2.4).  The IPC CT values of the samples were similar to the IPC CT 
values of the non-template controls indicate that little to no inhibition was occurring in the 
samples.  However, the differences between samples processed with stainless steel pulverization 
components and polycarbonate suggests that undetectable inhibition is still occurring.  The 
difference in recovered DNA quantity between samples pulverized with stainless steel or 
polycarbonate was significant at the 95% confidence level (large autosomal target t(32) = 4.54 p 
<001, small autosomal target t(31) = 4.73 p <001, Y target t(32) = 3.53, p < 0.001) (Fig. 2.22). 
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Figure 2.22:  Nuclear DNA quantification data from human rib samples.  Error bars represent ± 
95% CI. 
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Dilution studies with mtDNA from the same human rib suggest that when samples were 
diluted, no significant difference in DNA recovery was observed whether the samples were 
processed with stainless steel or polycarbonate.  This suggests that inhibition is still occurring in 
the samples although not detected by a relative increase in the IPC CT.  
 
 
 
 
 
Table 2.4 ANOVA statistical analysis of lysis buffer and pulverization component performance 
with human rib 
 
 
 
 
 
Pulverization 
component 
Nuclear target df 
(between,within) 
F value p value 
Polycarbonate Large Autosomal 2,9 1.40 
 
0.30 
 
Small Autosomal 2,9 0.57 
 
0.59 
 
Y 2,9 0.44 
 
0.66 
 
Stainless Steel Large Autosomal 2,19 1.91 
 
0.16 
 
Small Autosomal 2,19 1.91 
 
0.18 
 
Y 2,19 2.11 
 
0.15 
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2.11.2. Nuclear DNA Quantification from Human Femur 
When samples from a human femur were quantified for nuclear DNA, it was observed 
that the IPC CT values of the bone samples were similar to the IPC CT values of the non-template 
controls, indicating that little to no inhibition was occurring in the amplification of the samples.  
However, the differences between samples processed with stainless steel pulverization 
components and polycarbonate was significant at the 95% confidence level from the large and 
small autosomal targets but not for the Y targets (large autosomal target t(47) = 2.34, p = 0.02, 
small autosomal t(47) = 2.34 p = 0.02, Y target t(47) = 1.92, p = 0.06) (Fig. 2.23).  Again, as in 
samples processed from ribs, it is likely that inhibition is still occurring in samples processed 
with stainless steel, but the effects may not be as dramatic with smaller targets.  In addition, the 
overall performances of the lysis buffers is similar to what is observed from the mtDNA 
quantification data (Fig. 2.23).   
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Figure 2.23:  Nuclear DNA quantification data from human femur samples.  Error bars represent 
± 95% CI. 
 
 
 
The difference in effectiveness of each lysis buffer was not found to be significant at the 
95% confidence level between samples from a femur processed with either stainless steel or 
polycarbonate impactor bar and end cap (Table 2.5).  
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Table 2.5: ANOVA statistical analysis of lysis buffer and pulverization component performance 
with human femur 
 
 
 
 
 
 
 
 
 
 
  
Pulverization component Nuclear target df 
(between,within) 
F p value 
Polycarbonate Large Autosomal 2,21 0.23 
 
0.80 
Small Autosomal 2,21 0.40 
 
0.68 
Y 2,21 0.55 
 
0.59 
 
Stainless Steel Large Autosomal 2,23 0.98 
 
0.39 
Small Autosomal 2,26 1.45 
 
0.25 
 
Y 2,23 1.49 
 
0.25 
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CHAPTER 3: DISCUSSION 
 
3.1. Evaluation of Inhibition in Bone Samples 
Bone tissue is considerably more resistant to degradation than other bodily tissues and as 
a result is often the only physical evidence available for the identification of human remains.  
The unique composition of bone makes it resistant to breakdown but also poses associated 
challenges with DNA extraction, resulting in tremendous difficulty for the forensic typing 
community.  The mineral and collagen matrix creates a physical barrier, and the components of 
this bone matrix are known to be PCR inhibitors (Ye et al. 2004, Loreille et al. 2007).  The 
environment from which the bone is found potentially provides another source of PCR 
inhibition, as well as any chemical treatments performed post mortem to preserve the bone (Ye et 
al. 2004, Kalmár et al. 2000).   
It was found in this study that the coextraction of PCR inhibitors apparently caused the 
greatest variation in the amount of mtDNA recovered within the same bone types.  However, it is 
unlikely that the inhibition observed originates from a single source.  This work presents some 
preliminary observations and suggestions for future work in enhancing mtDNA recovery from 
bones and reducing the coextraction of PCR inhibitors.  In addition, it is suggested that future 
work focus on elucidating the sources of inhibition present utilizing a variety of technologies, 
including spectrometric analysis. 
3.1.1. Evaluation of Lysis Buffer Performance and Different Types of Bone 
Initial efforts focused on the use of different lysis buffers in a standard extraction 
protocol (FBI 2010).  The effectiveness of the three different lysis buffers evaluated in this study 
varied considerably when different bone types were examined.  The femur used in this study 
routinely yielded higher quantities of mtDNA than the ribs studied, regardless of the lysis buffer 
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used.  Traditionally, weight-bearing long bones have been regarded as the optimum choice for 
DNA recovery, likely due to better DNA preservation (Mundorff et al. 2009).  Additional studies 
suggest that higher quantities of DNA can be recovered from metatarsals and phalanges.  It is 
possible that cancellous bone in some situations may contain more cellular material associated 
with increased vascularization (Miloš et al. 2007); however, this appears dependent upon the 
preservation of the actual bone (Prinz et al. 2007, Mundorff et al. 2009).  The bones in this study 
contained no visible cellular tissue and were processed with hydrogen peroxide; therefore, the 
DNA was likely better preserved in the dense cortical bone of the femur.    
Overall, at the 95% confidence level, no difference in effectiveness of different lysis 
buffers was observed in the recovery of mtDNA per gram of bone material for femur or rib 
samples.  However, the effectiveness of each lysis buffer varied considerably depending on the 
particular bone sampled.  mtDNA recovery and inhibition varied greatly with some bone samples 
but not in others.  In addition, the region sampled in the bone affected mtDNA recovery and the 
amount of inhibition observed.  
To further understand the inhibition occurring in bone extracts, samples from a femur and 
two ribs were diluted in a series and the mtDNA quantified.  The result of these dilution studies 
was that when femur and rib samples were diluted and re-quantified, it was found that at a 1:10 
dilution, no difference in the quantity of recovered mtDNA with each lysis buffer could be 
observed at the 95% confidence level, suggesting that the difference in performance of each lysis 
buffer was due to the interaction between the lysis buffer and inhibitors present in the mtDNA 
extract and not a true difference in actual quantity of recovered mtDNA.         
Analyzing the apparent mtDNA recovery in neat samples and 1:2 dilutions illustrated a 
difference in the performance of each lysis buffer when detectable inhibition was present.  In 
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cases where rib samples showed high levels of inhibition, lysis buffer ATL was not found to be 
as effective as buffers SEB and BTA, which contain the divalent metal chelating agents EDTA 
and EGTA, respectively.  The dilution series performed with a large rib resulted in no apparent 
mtDNA recovery at the neat and 1:2 dilutions.  However, at the 1:10 dilution, it was possible to 
quantify mtDNA from the extract.  Moreover, the mtDNA recovery from the rib samples diluted 
1:10 was not found to be significantly different at the 95% confidence level than in samples 
treated with the lysis buffers SEB or BTA.   Furthermore, no difference was observed in the 
sample IPC CT values relative to the non-template controls, indicating no difference in the 
performance of each lysis buffer when inhibitors are sufficiently diluted.   
  A similar trend was observed in a smaller rib.  Neat samples processed with buffer ATL 
exhibited no apparent mtDNA recovery, but did show mtDNA recovery occurring at the 1:2 and 
1:10 dilutions.  As seen in the other rib samples, no difference in the performance of the three 
lysis buffers was observed at the 1:10 dilution at the 95% confidence level.  In addition to 
differences in mtDNA recovery, this variation in lysis buffer effectiveness was illustrated by the 
sample IPC CT values.  For rib samples processed with buffer ATL, the sample IPC CT values 
were undetermined in all neat samples and either undetermined or elevated relative to the NTC 
IPC CT in 1:2 dilutions.  At the 1:10 dilution all samples had an IPC CT value that was not 
different from the NTC IPC CT values, where no inhibition is expected.  It is noteworthy that the 
sample IPC CT values were on average one cycle lower than observed in the reagent blanks.  This 
suggests that the source of inhibition detected in the reagent blanks is something that can be 
diluted out.             
Femur samples that were diluted and re-quantified showed no difference in the 
performance of each buffer relative to one another and no change in the IPC CT values.   In 
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addition, the IPC CT values observed in the 1:10 dilution fell below the IPC CT values of the 
reagent blanks and were similar to those observed in the NTCs.  This suggests that inhibition is 
occurring in the reagent blanks as the IPC CT values were not only a cycle higher than observed 
in the NTCs but also in diluted samples.  This inhibition appeared to be caused by reagent 
carryover from the extraction process and may be an additional source of inhibition in bone 
extracts.    
The chemistry and reagents used throughout the extraction method may also be a source 
of inhibition, as seen in the elevated reagent blank IPC CT values as compared to NTCs.  This 
increase in the IPC CT from potential reagent carryover is troubling because it makes it more 
difficult to assess inhibition using this qPCR assay.  The increase in IPC CT of the reagent blank 
indicates that low levels of inhibition are present, which may be carryover reagents used in the 
extraction process.  In addition, pH may be a factor, not only in the binding of DNA to the 
column, but also in that any reagent carryover that alters the pH of the final eluted DNA may 
affect the pH of the qPCR reaction and performance of the polymerase.  It is possible that the 
bone lysate, including carryover EDTA from the demineralization step, may be affecting the pH 
of the samples and consequently affecting the binding affinity to the spin column.        
Because buffer ATL was generally effective on femur samples but not as much with 
inhibited rib samples, a chelating agent, EDTA, was added to a final concentration of 10 mM in 
an attempt to improve its performance.  However, the addition of 10 mM EDTA caused a 
reduction in the effectiveness of buffer ATL, possibly by affecting the pH or also potentially 
sequestering divalent magnesium cations in the downstream PCR reaction.  Divalent magnesium 
is a critical cofactor for DNA polymerase and with insufficient magnesium present, it will appear 
as if samples are inhibited.  Extremely high levels of inhibition were observed in the neat 
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samples.  However, when samples were diluted 1:10, there was no difference in the recovery of 
mtDNA between lysis buffers.  This indicates that the addition of EDTA is not likely interfering 
with the ability of the mtDNA to bind to the column, but may be interfering with the magnesium 
concentration and qPCR.  
It is possible that the elevated CT values observed in reagent blanks may be from EDTA 
carryover from the demineralization process.  However, no difference was observed in the 
reagent blank IPC CT values when different lysis buffers were used.  More washes may be 
necessary after the demineralization incubation.  If this inhibition is the result of EDTA 
carryover from the demineralization step, this could be ruled out by running a reagent blank that 
does not undergo the demineralization incubation step.     
3.1.2. Pulverization Method Effects on Inhibition 
Preliminary data with lysis buffers suggested that inhibition was the cause of the 
variation observed in many samples. In this study, a slight difference in lysis buffer effectiveness 
was observed in samples with low levels of inhibition. Through these experiments, a slight 
discoloration of the bone powder was sometimes observed, and what appeared to be metal debris 
was present in the spin column following purification.  It was suspected that metal that chipped 
off of the stainless steel end caps and impactor bar during pulverization in the freezer mill may 
be causing some inhibition in samples.  Polycarbonate end caps and impactor bar were utilized in 
an attempt to remove this potential source of inhibition.        
The use of stainless steel end caps and impactor bar with the freezer mill for the 
pulverization of bone fragments into a powder was found to introduce PCR inhibitors into the 
bone powder that remained in the bone extract.  This inhibition was observed as an increase of 
the IPC CT relative to the non-template control IPC CT, as well as a significant decrease in 
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recovered mtDNA as compared to samples from the same bone material that were pulverized 
with polycarbonate materials.  Therefore, It is possible to avoid this introduction of inhibitors by 
utilizing polycarbonate end caps and impactor bars in the pulverization process.  Chromium and 
iron were not detected by ICP-OES, so it is inconclusive if they are causing the observed 
inhibition. 
3.1.3. Bone Powder Quantity and Inhibition 
mtDNA extracts from bone often contain PCR inhibitors from the environment, the 
extraction process, and even from the bone itself.  Divalent calcium ions from the mineral matrix 
of osseous tissue are known to inhibit PCR; however, it is unknown if calcium is present in the 
mtDNA extract after the entire extraction process and is therefore causing inhibition.  In an 
attempt to reduce the levels of inhibition observed in samples believed to be caused by calcium, 
the sample input of bone powder for each extraction was reduced by one half, from 0.1 g to 0.05 
g.  If the inhibition occurring in samples was in fact due to the mineral matrix, in particular, 
divalent calcium ions, then it was expected that decreasing the ratio between bone powder to 
chelating agent in the demineralization incubation would reduce inhibition seen in samples.  The 
results showed no difference in the levels of inhibition detected by the IPC CT, and no difference 
in the recovery of mtDNA per gram of bone material.  This further suggests that calcium is not a 
major source of inhibition in the samples that were processed in this study.   
3.1.4. Assessment of Inhibition by Calcium with ICP-OES 
Samples processed with either stainless steel or polycarbonate were both quantified with 
qPCR to assess the levels of inhibition and then analyzed with ICP-OES to measure the amount 
of calcium present.  Even though the qPCR results indicated extremely high levels of inhibition 
in samples processed with stainless steel and less inhibition in samples processed with 
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polycarbonate, the quantities of calcium measured in both samples were similar, further 
suggesting that the stainless steel is a key source of inhibition, more so than the previously 
suspected divalent calcium.  However, because inhibition was still detected in samples processed 
with polycarbonate, the stainless steel is evidently not the only source of PCR inhibitors in bone 
tissue.   
When additional samples from a human rib were processed and then quantified, the 
qPCR data indicated moderate levels of inhibition, although much less than that observed from 
the previous rib studied.  When compared to the samples processed from a different rib, the 
recovered quantities of mtDNA were different.  However, the more inhibited samples contained 
1.334 ppm (0.033 mM) of calcium and the less inhibited samples contained 1.962 ppm of 
calcium (0.049 mM).  The inhibition assay performed with CaHPO4 showed a 17% decrease in 
mtDNA recovery at a concentration of 33.6 μM.  This suggests that calcium, although present in 
samples and likely contributing to some inhibition observed, is not the major contributing source 
of inhibition in purified mtDNA extracts from bone using these extraction methods.  
3.2. A Preliminary Look at Different Purification Systems 
No significant difference in mtDNA recovery was observed at the 95% confidence level 
when Prepfiler® was used to purify the mtDNA from bone lysate and compared side by side 
with QIAamp®.  However, Prepfiler® has its own manufacturer protocol for processing bone 
samples and the use of it in the extraction method used in this study may not have been 
optimized for bone samples.  It is not possible to properly assess the performance of the Qiagen 
QIAamp® spin columns and Prepfiler® magnetic bead-based purification systems until the 
conditions for each have been optimized for bone tissue.  It was observed that the IPC CT of the 
reagent blanks of samples processed with Prepfiler® were one cycle threshold lower on average 
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than those processed with QIAamp®.  In addition, the sample IPC CT values for samples 
processed with Prepfiler® were also on average one cycle lower than those processed with 
QIAamp®.  The bead-based system may be more efficient in the removal of inhibitors of PCR.  
On average, the quantity of recovered mtDNA from samples processed with Prepfiler® was 
significantly lower than that observed with samples processed with QIAamp® at the 95% 
confidence level; however, it may be possible to improve the performance of Prepfiler® through 
modifications of the method used in this study.  Because Prepfiler® was more effective in the 
removal of inhibitors than QIAamp®, additional work with Prepfiler® should be considered. 
3.3. Variation Caused by Kit Chemistry, pH, and Ionic Strength 
In addition, adjusting the volume of buffer AL added to bone samples should be 
evaluated in an effort to enhance mtDNA recovery and removal of inhibitors with the use of 
Qiagen QIAamp® spin column purification system.  With DNA extraction from bone, the 
increased substrate volume (300 μL from the lysis reaction in addition to the volume of the bone 
material in the reaction after the demineralization step) may be rendering the 300 μL of buffer 
AL insufficient in maintaining proper pH and ionic strength for the DNA to bind efficiently to 
the spin column.  The bone material itself may be affecting the pH of the reaction and 
consequently the ability of the DNA to bind to the spin column.  Previous studies have shown 
that reagents added to the bone material during the lysis incubation, such as EDTA and DTT, 
have been shown to raise the pH and affect DNA binding (Dukes et al. 2012).  Adjusting the 
volume of buffer AL may be enough to lower the pH as well as maintain a more optimal ionic 
strength for DNA binding in the presence of the chaotropic salts.  Inhibition of the IPC was 
reduced in a rib sample that was treated with approximately three times the suggested volume of 
buffer AL.  This may have occurred because the altered salt concentration and lower pH affected 
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the retention of proteins and other inhibitors from the column.  
The quantities of HL60 control DNA added to the purified and quantified bone extract 
showed no signs of inhibition in the presence of bone powder extract.  However, the bone extract 
itself does contain inhibitors, as seen in the quantification data and elevated IPC CT values.  This 
could indicate that the mtDNA already present in the extract buffered the added HL60 from the 
effects of inhibitors.  This dosage effect suggests a possible inhibitor mechanism of binding to or 
interacting directly with the bone-derived mtDNA.  
3.4. Nuclear DNA Quantification from Bone Samples 
Nuclear DNA quantified from bone samples yielded results similar to those observed 
with mtDNA quantification.  Dilution studies with mtDNA from the same human rib suggest that 
when samples were diluted, no significant difference in DNA recovery was observed regardless 
of whether the samples were processed with stainless steel or polycarbonate.  This suggests that 
inhibition is still occurring in the samples although not detected by a relative increase in the IPC 
CT.    
3.5. Future Directions for Research 
The process of optimizing a DNA extraction method for bone material should be 
attempted from the bottom up, beginning with the sampling technique and procedure.  The 
quantities of mtDNA recovered from different bone samples varied considerably based upon 
where the sampling was performed within the bone itself.  In the rib samples and femur samples 
the mtDNA recovery varied by several orders of magnitude based on where the bone was cut.  
Unfortunately, this phenomenon was not anticipated and locations of the bone where samples 
were taken were not catalogued thoroughly.  Moreover, previous work has shown inconsistent 
results as to determining optimum sampling sites as mtDNA concentration within bone tissue 
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can be hard to predict.  The densest bone does not necessarily always yield the most amplifiable 
mtDNA (Barta et al. 2014).  The recovery of mtDNA from bone varies considerably within the 
same bone based on sampling.  In challenging bone samples, it may not always be feasible to 
select an optimum sampling site, such as with very small fragments of bone.  The lack of 
consistency in predicting optimum sampling sites also makes this difficult.   
Inhibitors present in purified mtDNA extract from bone can be due to the structure and 
composition of the bone, from contamination from the pulverization process, as well as 
potentially from carryover of reagents used in the extraction process.  In addition, inhibition may 
be introduced from the environment in which the bone is recovered.  These studies have been 
performed on bones that were obtained commercially, and hence were not exposed to soil, 
contamination, or harsh chemical treatment (cleaned with dermestid beetle maceration followed 
by hydrogen peroxide bleaching).  Hence, these results provide insight into the sources of 
inhibition from the bone material itself and/or the extraction process, and not added from the 
environment.  This is critical to elucidate which inhibitors are inherently present in bone 
material.  
Calcium, while present in extracts, is not likely a significant source of inhibition in the 
samples.  Stainless steel has been observed to increase the levels of inhibition detected and 
therefore the use of polycarbonate is highly recommended to decrease inhibition in samples.  
Still, it is likely that there are additional sources of inhibition, and it is may be important to 
consider the organic content of bone tissue.  Collagenases could be introduced into the lysis 
incubation, in addition to increasing the quantity of proteinases utilized.   
The greatest challenge that occurred in this work was dealing with the presence of PCR 
inhibitors.  The focus of this work shifted from optimizing the use of different kit based 
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chemistries to elucidating the types of inhibitors present that will affect downstream 
amplification.  Because the bones used in this study were gently cleaned (beetle maceration) and 
not exposed to harsh environmental conditions, it was possible to gain insight as to the sources of 
inhibition from the bone itself as well as from the methods used to extract the mtDNA.                 
The data collected in this study suggests that calcium, although present and detectable in 
mtDNA extracts from bone, is not likely a significant source of PCR inhibitors in bone samples.  
Increasing the ratio between EDTA and bone powder was ineffective in enhancing mtDNA 
recovery via the removal of inhibitors.  Furthermore, in the preliminary data collected using the 
ICP-OES, there was not an apparent relationship between calcium concentration and the levels of 
inhibition observed.  
Additional substances naturally occurring in bone can be evaluated by the addition of 
proteases, possibly increasing the concentration of proteinase K added to the reaction or the 
addition of a collagenase.  Collagen is highly prevalent in bone tissue and will not be removed 
during the demineralization step.  Increasing the ratio between bone powder and EDTA failed to 
decrease the inhibition observed, which may suggest that any inhibitors found in the bone 
powder are organic in nature.  Because the samples used in that experiment were pulverized with 
polycarbonate, stainless steel carryover was clearly not a source of inhibition present.           
The reagents used throughout the extraction process are also a source of low levels of 
PCR inhibitors.  This was observed in each experiment by assessing the IPC CT of the reagent 
blanks.  The IPC CT values of the reagent blanks were consistently one cycle higher relative to 
the NTC IPC CT values, which is a difference on a scale of an order of magnitude.  Even in fairly 
robust bone samples, such as many femur cross section samples, this increase in the IPC CT was 
observed.  Because of the large volume and high concentration of EDTA used in the 
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pulverization step, it is possible that some residual EDTA carried over into the purified mtDNA 
extract.  In addition, EDTA or EGTA is also present in two of the lysis buffers used in this work.  
EDTA can inhibit DNA polymerase by sequestering Mg2+, which is a necessary cofactor.  
However, it is less likely that EDTA from the lysis buffer is carrying over to the purified extract 
and more likely from the demineralization step, which is rich in EDTA.  This is likely due to the 
fact that reagent blanks for samples processed with lysis buffer SEB, BTA, and ATL showed no 
difference in the amount of inhibition observed of the IPC CT.  Should EDTA or EGTA from the 
lysis buffers SEB or BTA, respectively, be carried over, then one might expect that greater 
inhibition should have been observed in the reagent blanks. 
The increase in volume of Qiagen buffer AL in the beginning of the extraction step may 
be key in enhancing mtDNA recovery.  The increased mtDNA recovery as well as the decrease 
in the IPC CT, suggests that the conditions for the mtDNA to bind to the silica spin column may 
be suboptimal for this method.  The large volume of EDTA may affect the pH, as may the DTT 
or proteinase K.  It is possible that increasing the volume of buffer AL brought the pH back to 
the optimum level.  Previous work from Dukes et al. suggested that pH was a factor in their 
work, in which the addition of sodium acetate lowered the pH and enhanced the mtDNA 
recovery (2012).  This should be explored further in future work.  In addition, the larger sample 
volume may be diluting the chaotropic salts needed to facilitate binding to the column.  Adding a 
greater volume of buffer AL may have raised the ionic strength of the solution to the appropriate 
concentration required for optimum binding. 
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APPENDICES 
 
Appendix A: Examining the Effectiveness of Three Difference Lysis Buffers and 
Interactions with Different Bone Types 
 
 
 
Table A1: A comparison of quantities of mtDNA recovered from human femur and human rib 
using three different lysis buffers 
 
 
 
 
 
 
  
Bone Type Lysis Buffer Mean (copies/g) 95% CI (copies/g) 
Femur BTA 1.78 x 107 1 x 107 
SEB 1.98 x 107 9.9 x 106 
ATL 2.58 x 107 1.5 x 107 
Bone Type Lysis Buffer Mean (copies/g) 95% CI (copies/g) 
Rib BTA 1.42 x 106 2 x 106 
SEB 4.02 x 106 5 x 106 
ATL 5.26 x 105 1 x 106 
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Appendix B:  Comparison of Stainless Steel and Polycarbonate Pulverization Components 
 
 
 
Table B1: A compilation of data from different bone types and lysis buffers from samples 
processed with polycarbonate or stainless steel pulverization components. 
 
 
 
Table B2: Quantities of mtDNA recovered from human femur using three different lysis buffers 
and either stainless steel or polycarbonate freezer mill end caps and impactor bar 
 
 
 
 
 
 
 
Pulverization Component Mean (copies/g) 95% CI (copies/g) 
Stainless Steel 4.62 x 106 1.8 x 106 
Polycarbonate 2.07 x 108 2.3 x 107 
SPEX 
component 
Lysis Buffer Mean (copies/g) 95% CI (copies/g) 
Polycarbonate BTA 2.98 x 107 1 x 107 
SEB 3.71 x 107 8 x 106 
ATL 4.95 x 107 2 x 107 
SPEX 
component 
Lysis Buffer Mean (copies/g) 95% CI (copies/g) 
Stainless Steel BTA 8.17 x 106 4x 106 
SEB 8.23 x 106 5 x 106 
ATL 1.00 x 107 6 x 106 
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Table B3:  A comparison of quantities of mtDNA recovered from a large human rib when 
processed with either polycarbonate or stainless steel and diluted ten-fold 
 
 
  
SPEX 
Component 
Dilution Mean 
 (copies/2  μL) 
95% CI 
(copies/2 μL) 
Stainless Steel Neat 0 0 
Polycarbonate Neat 2,480.64 4 x 102 
Stainless Steel 1:10 54.05 1 x 102 
Polycarbonate 1:10 178.71 1 x 102 
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Appendix C:  Bone Sample Mass Effects on mtDNA Recovery from Human Femur 
 
 
 
Table C1:  Mean quantities of recovered DNA from small rib using three different lysis buffers 
and either 0.1g or 0.05 g bone powder 
 
  
Mean Sample Mass 
 (g) 
Lysis Buffer Mean 
 (copies/g) 
95% CI 
(copies/g) 
0.0506 SEB 3.70 x 107 4 x 106 
BTA 3.24 x 107 8 x 106 
ATL 3.95 x 107 3 x 106 
Total 3.63 x 107 4 x 106 
0.0965 SEB 3.71 x 107 1 x 107 
BTA 2.98 x 107 2 x 107 
ATL 4.95 x 107 2 x 107 
Total 3.88 x 107 1 x 107 
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Appendix D:  Dilution of Samples to Observe the Behavior of Lysis Buffers with Inhibitors 
 
 
 
Table D1: Observed DNA recovery for femur samples treated with lysis buffer BTA, SEB, or 
ATL, compared to the 1:10 dilution quantities and the interpolated expected value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lysis Buffer Neat 
Observed 
(Copies/2 μL)a 
Neat 
Expected 
(Copies/2 μL)a 
1:10 
(Copies/2 μL) 
% Difference from 
Expected Valueb 
BTA 5.57 x 104 4.66 x 104 4.66 x 103 1.64 
SEB 9.76 x 104 5.60 x 104 5.60 x 103 4.26 
ATL 1.01 x 105 7.38 x 104 7.38 x 103 2.69 
Lysis Buffer 1:2 
Observed 
(Copies/2 μL)a 
1:2 
Expected 
(Copies/2 μL)a 
1:10 
(Copies/2 μL) 
% Difference from 
Expected Valueb 
BTA 2.64 x 104 2.33 x 104 4.66 x 103 1.34 
SEB 4.65 x 104 2.84 x 104 5.60 x 103 6.60 
ATL 4.82 x 104 9.63 x 104 7.38 x 103 3.04 
aThe quantities of mtDNA recovered from the 1:10 were multiplied by ten and five, 
respectively to estimate the actual quantity of mtDNA present in neat and 1:2 diluted samples 
bThe difference is shown as a percent difference of the observed neat quantity and the expected 
quantities 
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Table D2: Observed DNA recovery for large rib samples treated with lysis buffer BTA, SEB, or 
ATL, compared to the 1:10 dilution quantities and the interpolated expected value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lysis Buffer Neat 
Observed 
(Copies/2 μL) 
Neat  
Expected 
(Copies/2 μL)a 
1:10 
(Copies/2 μL) 
% Difference 
from Expected 
Valueb 
BTA 2.76 x 103 2.21 x 103 2.21 x 102 24.90 
SEB 1.78 x 103 1.97 x 103 1.97 x 102 -9.63 
ATL 0 1.98 x 103 1.98 x 102 -100 
Lysis Buffer 1:2 
Observed 
(Copies/2 μL) 
1:2 
Expected 
(Copies/2 μL)a 
1:10 
(Copies/2 μL) 
% Difference 
from Expected 
Valueb 
BTA 2.85 x 103 1.10 x 103 2.21 x 102 74.21 
SEB 3.57 x 103 1.09 x 103 1.97 x 102 67.22 
ATL 0 9.91 x 102 1.98 x 102 -100 
aThe quantities of mtDNA recovered from the 1:10 were multiplied by ten and five, 
respectively to estimate the actual quantity of mtDNA present in neat and 1:2 diluted samples 
bThe difference is shown as a percent difference of the observed neat quantity and the 
expected quantities 
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Table D3: Observed DNA recovery for small rib samples treated with one of three lysis buffers 
compared to the 1:10 dilution quantities and the interpolated expected value 
 
 
 
  
Lysis Buffer Neat 
Observed 
(Copies/2 μL) 
Neat 
Expected 
(Copies/2 μL)a 
1:10 
(Copies/2 μL) 
% Difference 
from Expected 
Valueb 
BTA 1.22 x 103 7.09 x 102 7.09 x 101 -72.23 
SEB 9.29 x 102 4.76 x 102 4.77 x 101 -95.04 
ATL 0 6.11 x 102 6.11 x 101 100 
Lysis Buffer 1:2 
Observed 
(Copies/2 μL) 
1:2 
Expected 
 (Copies/2 
μL)a 
1:2 
(Copies/2 μL) 
% Difference 
from Expected 
Valueb 
BTA 2.18 x 102 3.55 x 102 7.09 x 101 -25.56 
SEB 2.64 x 102 2.38 x 102 4.76 x 101 8.50 
ATL 1.01 x 102 3.05 x 102 6.11 x 101 66.84 
aThe quantities of mtDNA recovered from the 1:10 were multiplied by ten and five, 
respectively to estimate the actual quantity of mtDNA present in neat and 1:2 diluted 
samples 
bThe difference is shown as a percent difference of the observed neat quantity and the 
expected quantities 
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Appendix E:  Addition of a Chelating Agent to Buffer ATL 
 
 
 
Table E1: A comparison of neat and 1:10 diluted mean DNA yields from rib samples using one 
of four different lysis buffers 
 
 
  
Lysis Buffer Neat Mean 
(Copies/2 μL) 
Neat 
 95% CI 
 (Copies/2 μL) 
1:10 Dilution 
Mean 
(Copies/2 μL) 
1:10 Dilution 
95% CI 
(Copies/2 μL) 
BTA 1.62 x 104 2 x 104 4.14 x 103 2 x 102 
SEB 3.04 x 104 6 x 103 5.06 x 103 7 x 102 
ATL 6.98 x 103 1 x 104 4.85 x 103 4 x 102 
ATL+10 mM EDTA 1.45 x 103 3 x 103 4.41 x 103 1 x 103 
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Appendix F:  Preliminary Work on Comparison of QIAamp® and Prepfiler® 
 
 
 
Table F1: Preliminary comparison of DNA recovery from human femur cross sections processed 
using two different commercial purification systems 
 
 
  
Pulverization 
Component 
Lysis 
Buffer 
Purification 
Method 
Mean 
(copies/g) 
95% CI 
(copies/g) 
Stainless Steel SEB QIAamp® 9.22 x 106 2 x 106 
Stainless Steel SEB PrepFiler® 6.93 x 106 2 x 106 
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Appendix G:  Results Inhibition Study 
 
 
 
Table G1: Quantities of mtDNA observed when different known quanities of HL60 DNA were 
added to purified DNA extract.   
 
 
  
HL60 
(pg/μL) 
Observed Sample Mean 
mtDNA (copies/2μL) 
IPC CT Expected  
(copies/2 μL)a 
10 pg/μL   1.76 x 103 ± 1.80 x 103 28.93 ± 1.71 1.67 x 104 ± 2.45 x 103 
1.67 pg/μL   5.05 x 103  ± 6.43 x 102 28.32 ± 0.83 4.81 x 103 ± 2.72 x 102 
0 pg/μL   2.49 x 103  ± 1.86 x 102 27.90 ± 0.15 1.97 x 103 ± 3.08 x 102 
NTC Undetermined 25.3925 ± 0.125 n/a 
a Expected quantities were calculated as the quantity of DNA from the positive control 
added to the mean of the samples containing 0 pg/μL  of HL60 
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Appendix H: Nuclear DNA Quantification from Human Rib and Human Femur 
 
 
 
Table H1: Nuclear DNA quantification data from human rib 
  
Pulverization 
Component 
Nuclear target Buffer Mean DNA  
(ng/g) 
95% CI 
(ng/g) 
Polycarbonate 
Large 
Autosomal 
SEB 0.15 0.1 
BTA 0.64 0.8 
ATL 0.26 0.3 
Small 
Autosomal 
SEB 2.91 2 
BTA 3.44 3 
ATL 4.76 3 
Y 
SEB 3.77 2 
BTA 4.52 5 
ATL 6.03 4 
Stainless Steel 
Large 
Autosomal 
SEB 0.05 0.05 
BTA 0.06 0.1 
ATL 0.07 0.08 
Small 
Autosomal 
SEB 0.25 0.2 
BTA 0.28 0.3 
ATL 0.46 0.5 
Y 
SEB 0.22 0.2 
BTA 0.24 0.3 
ATL 0.43 0.5 
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Table H2: Nuclear DNA quantification data from human femur 
 
 
 
Pulverization 
Component 
 Nuclear target Buffer Mean DNA  
(ng/g) 
95% CI 
(ng/g) 
Polycarbonate 
Large 
Autosomal 
SEB 1.79 2 
BTA 1.80 2 
ATL 2.47 3 
Small 
Autosomal 
SEB 8.58 2 
BTA 5.13 2 
ATL 8.30 9 
Y 
SEB 6.23 1 x 101 
BTA 3.74 5 
ATL 5.90 6 
Stainless Steel 
Large 
Autosomal 
SEB 0.74 0.7 
BTA 1.04 0.7 
ATL 0.86 0.5 
Small 
Autosomal 
SEB 3.50 3 
BTA 2.30 0.5 
ATL 3.78 2 
Y 
SEB 3.24 2 
BTA 1.92 1 
ATL 3.61 1 
